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Abstract 
Natural products have historically been a rich source of  “lead compounds” in 
drug discovery. The investigation of terrestrial plants and marine organisms 
aimed at searching new biologically active compounds is a central issue of 
this kind of studies, through structure elucidation combined with biological 
evaluation. My research work, described in this PhD thesis, falls within this 
research field and was addressed at three different topics: - i) isolation and 
structural elucidation of cytotoxic macrolides and depsipeptides and sterols 
active on PXR receptors from sponge Theonella swinhoei; ii) isolation and 
structural elucidation of metabolites modulating kinase activity from sponge 
Iotrochota purpurea; iii) isolation and analisys of correlation between 
reactivity and bioactivity for antimalarial and antinflammatory metabolites 
from the African plant Vernonia amygdalina. The structure elucidation of new 
molecules was performed using advanced spectroscopic techniques (2D-
NMR and MS) and advanced methods of stereochemical determination 
(Murata’s method and Marfey’s method). 
The chemical investigation of spongal metabolites carried out during my PhD 
was financed by the European project “Bluegenics”. Several structurally 
interesting bioactive molecules have been isolated from Theonella sp., namely 
swinholides (cyclic 44-member macrolides) and theonellapeptolides (cyclic 
tridecadepsipeptides with a large amount of non-ribosomial amino acids), 
both featuring in vitro antiproliferative activity and providing important 
information regarding structure-activity relationship. The class of 4-
methylensterols, typical of Theonella sponges, showed activity on nuclear 
receptor PXR, shedding light on structure-activity relationships useful for 
synthesis of lead compunds to be used for therapy of metabolic diseases.  
Regarding the second topic, the isolation of haloindole derivatives, by 
bioguided approach, allowed their evaluation for antikinase activity, which 
could have an important impact on the manipulation of cell proliferation, 
diabetes, and neurodegenerative disorders. 
Finally, a bioguided analysis of Vernonia amygdalina, a plant from Africa used 
as foodstuff and as drugs in the folk medicine, allowed the characterization of 
plant extracts for stage specific effects on gametocytes and sporogonic stages 
Abstract 
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of Plasmodium and identification of compounds responsible for antimalarial 
activity. In particular, leaves of V. amygdalina contain sesquiterpenes 
lactones vernolide and vernodalol featuring this kind of activity; thus, they 
have a potential for drug discovery and for the development of standardized 
V. amygdalina based phytomedicines. The second aim of the investigation on 
V. amygdalina was the isolation and structural elucidation of a series of 
sesquiterpenes compounds with Michael related bioactivity, capable of 
shedding light on the molecular mechanisms underlying the anti-
inflammatory and anticancer activities detected for the extract. On these 
series,  cysteamine assay proved to be a tool to build a sort of Michael-oma 
profile of this class of metabolites, identifying the most reactive site in 
polyfunctional compounds and ranking them in terms of reactivity. 
Considering the correlation between thia-Michael acceptor reactivity and 
modulation of important biological target, sesquiterpene lactones were 
evaluated on transcription factors NF-κB, STAT3 and Nrf2 involved in cancer 
initiation and progression, concluding that vernolide is the major anti-
inflammatory constituent of extracts and elucidating the anticancer activity 
reported.  
Abstract (in italiano) 
I composti di origine naturale costituiscono storicamente una ricchissima 
fonte di “lead compound” utili al processo di drug discovery. In questo 
ambito, la ricerca di nuove molecole biologicamente attive da piante ed 
organismi marini costituisce un capitolo centrale, attraverso la 
determinazione strutturale combinata alla valutazione dell’attività biologica. 
Il lavoro di ricerca descritto in questa tesi di dottorato si è inserito in questo 
campo, ed è stato indirizzato a tre diversi topic: i) isolamento e 
determinazione strutturale di macrolidi e depsipeptidi citotossici e steroli 
attivi sui recettori PXR dalla spugna Theonella swinhoei; ii) isolamento e 
determinazione strutturale di metaboliti aventi attività modulatrice sulle 
chinasi dalla spugna Iotrochota purpurea; iii) isolamento e analisi della 
correlazione tra bioattività e reattività per metaboliti antimalarici ed 
antinfiammatori dalla pianta Vernonia amygdalina. La determinazione 
Abstract 
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strutturale delle nuove molecole isolate è stata effettuata utilizzando 
metodologie spettroscopiche avanzate (2D-NMR e MS) e tecniche per la 
determinazione della stereochimica (metodi di Marfey e di Murata). 
L'analisi chimica di metaboliti provenienti da spugne condotta durante il mio 
dottorato è stata finanziata dal progetto europeo Bluegenics. Diverse 
molecole bioattive, molto interessanti da un punto di vista strutturale, sono 
state isolate da Theonella sp.: swinholidi (macrolidi ciclici a 44 termini) e 
theonellapeptolidi (tridecadepsipeptidi ciclici ricchi in aminoacidi non 
ribosomiali), che hanno mostrato in vitro un’azione antiproliferativa che ha 
fornito importanti informazioni riguardo alle relazioni tra struttura delle 
macromolecole ed attività. La classe dei 4-metilensteroli, molecole 
caratteristiche delle spugne Theonella sp., hanno mostrato un’attività 
modulatrice sui recettori nucleari PXR, facendo luce sulle relazioni tra 
struttura e attività utili alla sintesi di lead compunds per la terapia di disturbi 
metabolici. 
Riguardo il secondo topic, l’isolamento di derivati aloindolici, tramite un 
approccio bioguidato, ha permesso la valutazione dell’attività antichinasica, 
che potrebbe avere un forte impatto sulla modulazione di proliferazione 
cellulare, diabete e disordini neurodegenerativi. 
Infine, l’analisi fitochimica della pianta africana Vernonia amygdalina, 
utilizzata come alimento e come farmaco nella medicina tradizionale, ha 
condotto alla caratterizzazione degli estratti per gli effetti stadio-specifici 
sulle fasi gametocitica e sporogonica del ciclo vitale di Plasmodium e 
l’identificazione dei composti responsabili dell’attività antimalarica. In 
particolare, le foglie di V. amygdalyna contengono i lattoni sesquiterpenici 
vernolide e vernodalolo dotati di questo tipo di attività, evidenziando il 
potenziale della pianta per il drug discovery e per lo sviluppo di un 
fitofarmaco basato su estratti standardizzati. Il secondo obiettivo è stato 
l'isolamento e la determinazione strutturale di una serie di composti 
sesquiterpenici, aventi bioattività correlata alla reattività di Michael, utile a 
far luce sui meccanismi molecolari che sono alla base delle attività 
antinfiammatoria ed anticancro già riportate in letteratura per gli estratti di 
questa pianta. Su questa serie di molecole, è stata, quindi, validata l’utilità del 
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saggio della cisteamina nella creazione di un profilo Michael-oma di questa 
classe di metaboliti, identificando il sito più reattivo nei composti 
polifunzionali e stabilendo un ranking di reattività tra questi composti. In 
considerazione della correlazione tra reattività di tipo thia-Michael e 
modulazione di importanti target biologici, è stata effettuata la valutazione 
dei lattoni sesquiterpenici sui fattori di trascrizione NF-κB, STAT3 e Nrf2, 
coinvolti nelle fasi iniziali e nel progredire delle patologie cancerose, 
individuando nel vernolide il composto con maggiore attività 
antinfiammatoria dell’estratto e dando una spiegazione all'attività anticancro 
riportata per la pianta. 
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CHAPTER 1 - INTRODUCTION 
1.1 NATURE AS INSPIRATION 
Natural products can be considered the foundation of the pharmaceutical 
industry. Despite a period in which pharmaceutical companies cut back on 
their use of natural products in drug discovery, there are many promising 
drug candidates in the current development pipeline that are of natural 
origin and today natural product-based drug discovery is experiencing a 
renaissance. Technical drawbacks associated with natural product research 
have been lessened, and there are better opportunities to explore the 
biological activity of previously inaccessible sources of natural products. 
With the increasing acceptance that the chemical diversity of natural 
products is well suited to provide the core scaffolds for future drugs, there 
will be further developments in the use of novel natural products and 
chemical libraries based on natural products in drug discovery campaigns. In 
particular, the marine environment, a rich source of structurally unique, 
bioactive metabolites, has produced a number of drug candidates that are 
currently in clinical trials. In the everexpanding search for sources of new 
chemical diversity, the exploration of deep-sea fauna has emerged as a new 
frontier in drug discovery and development. 
Natural products have inspired many developments in organic chemistry, 
leading to advances in synthetic methodologies and to the possibility of 
preparing analogues of the original lead compound with improved 
pharmacological or pharmaceutical properties. Natural product scaffolds 
have also been well recognized as being ‘privileged’ structures in terms of 
their ability to be the basis for successful drugs. Such scaffolds are being used 
as cores of compound libraries made by combinatorial techniques. With the 
application of various techniques to create analogues and derivatives of 
natural products, it becomes possible to derive novel compounds that can be 
patented, even when the original structure was previously disclosed. 
Plants and marine organisms produce many biologically active substances for 
defense and other ecological purposes, and so these substances are uniquely 
tailored to fit into a biological receptor of some kind: this is one of the several 
Chapter 1- Introduction 
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reasons why natural products have proved to be such a prolific source of 
bioactive agents. Natural products are often large molecules with built-in 
chirality and are thus uniquely suited to bind to complex proteins and other 
biological receptors. As a result of these considerations, there is a high 
correlation between the properties of drugs and those of natural products. 
The research work described in this PhD thesis has been performed at the 
Department of Pharmacy of Università di Napoli "Federico II" and, for a 
semester, at CNRS-Paris. It was addressed at different aspects of the research 
on marine and terrestrial natural products, with special attention to the "core 
activity" of natural product chemistry, i.e. isolation and structure elucidation 
of new bioactive compounds.  
The activity described in this phD thesis followed three different research 
projects:  
a) Isolation and structural elucidation of cytotoxic macrolides and 
depsipeptides and PXR-modulating steroids from Indonesian sponge 
Theonella swinhoei. 
b) Isolation and structural elucidation of metabolites modulating kinase 
activity from Indonesian sponge Iotrochota purpurea. 
c) Isolation and analysis of correlation between reactivity and bioactivity for 
antimalarial and antinflammatory metabolites from African plant Vernonia 
amygdalina. 
The results obtained during my Ph.D. have been reported in seven  papers 
(listed at the end of this chapter) already published or submitted for 
publication. 
1.1.1 An historical perspective1-2 
For centuries China led the world in the use of natural products for healing. 
Shen Nung Pen Ts’ao is a detailed report of Chinese herbs which lists 385 
materials. Pen Ts’ao Ma catalogue, written by Li-Chen during the Ming 
Dynasty, (1573–1620) mentions 1898 herbal drugs and 8160 prescriptions. 
The number of medicinal herbs used in 1979 in China numbered 5967. One 
of the most famous Chinese folk herbs is the ginseng (Panax ginseng) root, 
used for treatment of various diseases. The active principles were thought to 
Chapter 1- Introduction 
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be the saponins called ginsenolides. The extract of the Ginkgo tree, Ginkgo 
biloba L., another popular medicine, can improve memory and sharpen 
mental alertness. The Indian hemp plant, Cannabis sativa, has been used since 
3000 BC, and it is also used as marijuana or hashish. Its constituent, Δ9-THC 
(tetrahydrocannabinol) is responsible for its mind-altering effect. Mechoulam 
has been the principal scientist in this field and the first to elucidate the 
structure of Δ9-THC. During the 17th century, the Jesuits brought with them 
from South America the bark of the cinchona Cinchona officinalis (called 
quina-quina by the Indians) for the treatment of malaria. In 1820, active 
compound quinine has been isolated from the China tree. Alkaloids are the 
major constituents of the herbal plants and the extracts used for centuries, 
but it was not until the early nineteenth century that the active principles 
were isolated in pure form, for example morphine (1816), atropine (1819). It 
was a century later that the structures of these compounds were finally 
elucidated. Modern methods used to separate complex organic mixtures can 
separate samples rapidly and efficiently in the picogram range. This has been 
impossible until recently. Among the recent outstanding contributions to the 
chemistry of natural products is the conformational analysis designed by 
Derek Barton. Using conformational analysis, he determined the structures of 
many key terpenoid. Robert B. Woodward was involved in the structural 
determinations of penicillin, strychnine, patalin, terramycin, aureomycin and 
the synthesis of Vitamin B12. His paper published in 1941-42 on empirical 
rules for estimating the absorption maxima of enones and dienes made the 
general organic chemical community realize that UV could be used for 
structural studies, thus launching the beginning of the spettroscopic 
revolution which soon brought on the applications of IR, NMR and MS. As 
chemical techniques improved, the active constituents were isolated from 
plants, were structurally characterized, and in due course, many were 
synthesized in the laboratory. Sometimes, more active or better tolerated 
drugs were produced by chemical modification (semi- synthesis), or by total 
synthesis of analogues of the active principles.  
The investigation on the biosynthesis, a metabolic sequences leading to 
various selected classes of natural products, is of pivotal importance in 
Chapter 1- Introduction 
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Natural Product Chemistry. The term natural product is generally used to 
mean a secondary metabolite: a small molecule that is not essential to the 
growth and development of the producing organism. Such compounds are 
found only in specific organisms, or group of organisms, and are an 
expression of the individuality of species. Well over 300,000 secondary 
metabolites probably exist. Unraveling the biosynthetic pathways by which 
natural products are made is difficult and time-consuming work, but is 
fundamental to understand how organisms function at the molecular level. 
The molecules are sometimes complex, but the building blocks for their 
biosynthesis derived from primary metabolism. It has been established that 
the primary synthetic process in nature is photosynthesis by which green 
plants utilize the energy of the sun for the production of organic compounds 
from carbon dioxide. The initial products of photosynthesis are 
carbohydrates. Further metabolic alterations lead to the formation of a pool 
of organic compounds of low molecular weight and simple structures such as 
carboxylic- and amino acids, which are vital for the living organisms. They 
form the synthetic starting materials for specific, genetically controlled, 
enzymatically catalyzed reactions that lead to the complex compounds that 
characterize the secondary metabolism of plants and mammals. In many 
cases, a suitable cofactor, e.g. NAD+, PLP, HSCoA, as well as the substrate, may 
also be bound to participate in the transformation. Enzymes have the power 
to effect these transformation more efficiently and more rapidly than the 
chemical analogy, and also under very much milder conditions. Where 
relevant, they also carry out reactions in stereospecific manner. Some of the 
important reaction frequently encountered are alkylation, oxidation and 
reduction, decarboxylation, aldol and Claisen reactions. 
The reaction pathway leading to a particular natural product is called the 
biosynthetic pathway and the corresponding event is known as biogenesis. 
By far the most important building blocks employed in the biosynthesis of 
secondary metabolites are derived from the intermediates acetyl coenzyme A 
(acetyl-CoA), shikimic acid, mevalonic acid, and 1-deoxyxylulose 5-phoshate. 
These are utilized respectively in the acetate, shikimate, mevalonate, and 
deoxyxylulose phosphate pathways.  
Chapter 1- Introduction 
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1.1.2 The marine environment 
The study of marine natural products is considerably far behind that of 
compounds of terrestrial origin due to the difficulty in collection and 
identification of marine organisms. However, in spite of these difficulties, the 
marine environment has proven to be a very rich source of extremely potent 
compounds that have demonstrated significant activities in antitumor, anti-
inflammatory, analgesia, immuno-modulation, allergy, and antimicrobial 
assays.3 Bioactive products have been isolated from animals and plants as 
well as from marine microorganisms such as bacteria and fungi, protozoa and 
chromista. 
The oceans cover more than 70% of the earth’s surface and contain more 
than 300,000 described species of plants and animals.4-5Macroscopic 
organisms have adapted to all regions of the oceans, including polar, 
temperate, and tropical areas. The diversity in species is extraordinarily rich 
on coral reefs, where there are around 1,000 species per m2 in some areas, 
with the Indo-Pacific Ocean having the world’s greatest tropical marine 
biodiversity. The number and the activity of the natural products is directly 
related to the level of biodiversity of a marine area. The most interesting and 
promising marine natural products are small- to medium- molecular weight 
compounds produced principally by marine invertebrates (sponges, 
tunicates, soft corals) and microbes that have stimulated interdisciplinary 
studies by chemists, biologists and pharmacologists. The incredible potential 
of even a single marine organism to produce a large array of secondary 
metabolites can be interpreted by considering the common features of the 
secondary metabolism in all the living organisms as well as some peculiar 
features of the marine environment. Secondary metabolites play an essential 
role for the adaptation of the producer organism to the environment, mainly, 
but not uniquely, in terms of defence; they are practically the sole tool in the 
hands of organisms at lower evolutionary levels or lacking of mechanical or 
morphological way for protecting themselves (this is the case of sessile 
organisms as plants, algae, and the marine invertebrates sponges, tunicates, 
and bryozoans). 
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For all the reasons above summarized, it is not surprising that a thorough 
chemical analysis of a single marine invertebrate, carried out with non-
destructive modern spectroscopic techniques (allowing the stereostructure 
elucidation of molecules isolated in the low milligram range) can afford tens, 
when not hundreds, of secondary metabolites. These products provide a rich 
source of chemical diversity that can be fruitfully used as a “natural 
combinatorial library”, frequently more rich and chemically diverse than the 
libraries obtained through the use of synthetic combinatorial chemistry. 
Ideally, this “natural library” can be screened in order to find lead 
compounds to be used as inspiration to design and develop new potentially 
useful therapeutic agents and to gain the first information about the 
structure-activity relationships.  
In spite of the difficulties associated with the limited availability of the 
compounds under investigation, which is strictly related to the limited supply 
of the biological material correctly protected for environmental concerns, 
some interesting results have been obtained. Through the combined efforts 
of marine natural product chemists and pharmacologists, an astounding 
array of promising compounds have been identified. Some of these molecules 
are either at advanced stages of clinical trials or have been selected as 
promising candidates for extended pre-clinical evaluation. The majority of 
these products fall within the area of antimicrobial and cancer therapies. Just 
to cite an example, ecteinascidin 743 (ET-743): the Spanish company 
PharmaMar licensed the compound from the University of Illinois before 
1994. It is sold by Zeltia and Johnson and Johnson under the brand name 
Yondelis. It is approved for use in Europe, Russia and South Korea for the 
treatment of advanced soft tissue sarcoma. It is also undergoing clinical trials 
for the treatment of breast, prostate, and paediatric sarcomas. 
1.2 TECHNIQUES AND METHODS 
Recently, natural products chemistry has undergone explosive growth due to 
advances in isolation techniques, synthetic and biosynthetic approaches as 
well as spectroscopic and chromatographic methods. For the discovery of 
new compounds from natural source it is important to characterize these 
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new compounds in a non-destructive way, with submilligram samples. The 
study of natural compounds can be divided in the following steps:  
 Isolation and purification from biologic material; 
 Structural determination; 
 Determination of absolute and relative configuration 
1.2.1 Isolation procedures  
The isolation of natural products from the producing organisms poses 
numerous problems, because these compounds may only be present in 
infinitesimal quantities. The nature of the separation problem varies 
considerably, from the isolation of small quantities (milligrams or less) for 
structure determination purposes to the isolation of very much larger 
amounts (hundred milligram to gram quantities) for comprehensive 
biological testing, for semi-synthetic work or even for production of 
therapeutic agents. For these purposes, a good selection of different 
techniques is really important. The problem of separation and isolation of 
new metabolites from natural sources was solved with the development of 
techniques, such as the various analytical and preparative chromatographic 
methods.  
First, biological materials is extracted with an organic solvent, such as 
methanol. Then, the crude extract is partitioned between solvent with 
different polarity. In some cases, a modified Kupchan’s partitioning 
methodology6 has been used in this research. In this procedure, the 
composition of aqueous phase is adjusted sequentially as follows (Scheme 
1.1). 
 The methanol extract is dissolved in a mixture of 10% H2O/MeOH and 
partitioned against n-hexane; hexane extract obteined is rich in 
lipophilic compounds. 
 The water content (% v/v) of the MeOH extract is adjusted to 30% and 
partitioned against CHCl3; in this extract compounds with medium 
polarity were usually found. 
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 MeOH is removed from the aqueous phase by evaporation, and then  
the aqueous phase is extracted with n-BuOH; this final extract 
contains polar compounds. 
In this way, four extracts (n-hexane, CHCl3, n-BuOH and H2O extracts) can be 
obtained. Crude extracts are further fractioned trough sequential 
chromatographic techniques. The initial stages of a separation procedure 
involve methods with a high loading capacity and cheap stationary phases -
these have traditionally been column chromatography with silica gel or 
liquid-liquid methods. Subsequent steps employ techniques which require 
smaller samples - HPLC, for example. 
 
 
Scheme 1.1 Modified Kupchan’s partitioning methodology. 
MPLC (Medium Pressure Liquid chromatography) is a preparative liquid-
solid chromatography: medium pressure is used to force liquid mobile phase 
through the solid stationary phase. MPLC is more efficient in resolution than 
the open-column and the separation involves a considerable gain in time. The 
solid stationary phase can be a normal phase, like silica gel, or bonded phase 
(RP-8, RP-18). The technique makes use of pressures of ca. 5-40 bar and can 
easily accommodate much larger sample loads (100 mg-100 g) than are 
generally applied in other separations.  
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High Performance (or High Pressure) Liquid Chromatography (HPLC) , both 
normal-phase and reverse-phase, is the most widely used chromatographic 
method, and finds application in the preparative separation of samples to 
“pilot” the preparative isolation of natural products (optimization of the 
experimental conditions, checking of the different fractions throughout the 
separation). On the whole, however, HPLC is commonly applied as the last 
step in purification processes affording pure compounds in high yields.  
Finally the structure of isolated compounds is characterized and molecules 
are submitted to pharmacological assays. 
1.2.2 Mass Spectrometry 
Mass Spectrometry is an analytical technique, particularly used in organic 
chemistry, which allows to measure molecular masses of unknown 
compounds and thus to determine their elementary formula. Unlike 
spectroscopic techniques, mass spectrometry is a destructive technique, and 
it is not based on the interaction between radiations and matter. Any 
molecule has first to be ionized and transferred to gas phase in the ion source 
and then it is transmitted to the mass analyzer where its mass properties are 
measured. These three fundamental steps of the process occur in three 
different parts of the mass spectrometer, namely ionisation source, analyser, 
and detector. In order to obtain a mass spectrum, ions in a gas-phase must be 
produced in the ion source. They are subsequently accelerated, by an electric 
field, until they get to a specific speed and they are transferred to the mass 
analyzer, which separate different ions on the base of their mass/charge 
(m/z) ratio. The separated ions are then measured on the detector and the 
results displayed. 
Most of compounds described in the following chapters have been analyzed 
by Electrospray Ionisation (ESI) mass spectrometry through an Orbitrap 
system.  
ESI mass spectrometry allows the determination of non-volatile molecules to 
be analyzed directly from the liquid phase (Fig.1.1). The electrospray process 
is governed by a large number of chemical and physical parameters that 
Chapter 1- Introduction 
10 
 
together determine the quality of the process. Its start and end can be defined 
by an electrical circuit that drives the spray of liquid-charged droplets. 
 
Figure 1.1 ESI mass spectrometry 
In this process, the biomolecule starts out as an entity or complex, usually 
charged and dissolved in a water-rich environment. At the end of the process 
the same biomolecule is represented and harvested through the orifice of a 
mass analyser as a series of ‘naked’ multicharged ions. In a vacuum, the 
biomolecular ions then are selectively analysed according to their 
mass/charge ratio. Because of the electric potential of the capillary, each 
droplet of the spray carries an excess positive or negative charge, and this 
causes extensive protonation or deprotonation of the molecules of the 
sample, which become ions. An uncharged carrier gas such as nitrogen is 
used to help the liquid to nebulize and the neutral solvent in the droplets to 
evaporate. 
Orbitrap is a new type of mass analyzer introduced by Makarov.7 The LTQ-
Orbitrap combines the most advanced Ion Trap and Fourier Transform 
technologies into a single instrument with unprecedented analytical power 
and versatility. The instrument provides a high mass resolution, accurate 
mass determinations, and MSn for routine high-throughput analysis. 
In an Orbitrap, ions are injected tangentially into the electric field between 
the electrodes and trapped because their electrostatic attraction to the inner 
electrode is balanced by centrifugal forces. Thus, ions cycle around the 
central electrode in rings. In addition, the ions also move back and forth 
along the axis of the central electrode. Therefore, ions of a specific mass-to-
charge ratio move in rings which oscillate along the central spindle (Fig.1.2). 
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The frequency of these harmonic oscillations is independent of the ion 
velocity and is inversely proportional to the square root of the mass-to-
charge ratio (m/z ).  
 
Figure 1.2 Ion trajectories in an Orbitrap mass spectrometer. 
By sensing the ion oscillation similar as in the FT-MS (Fourier transform 
mass spectrometry), the trap can be used as a mass analyzer. Orbitraps have 
a high mass accuracy (1-2 ppm), a high resolving power (up to 200,000). 
Currently, there are two commercial LTQ-Orbitrap instruments, the 
Discovery and XL models. One of the primary differences is that the XL has a 
linear octopole collision cell (absent in the Discovery model), in which 
collisional activation and fragmentation can be performed. Although this 
feature provides additional versatility to MS/MS experiments, the analytical 
performance and fundamental principles of operation of the Orbitrap 
analyzers in both instruments are identical.8 
1.2.3 Nuclear Magnetic Resonance 9-10-11 
Nuclear Magnetic Resonance (NMR) spectroscopy is a powerful and 
theoretically complex analytical tool used for structure elucidation of the 
isolated secondary metabolites. It involves re-orientations of nuclear spins 
with respect to an applied static magnetic field. In addition to standard 1H 
and 13C NMR spectra, 2D NMR experiments have been largely used in the 
course of my research activity. They are superior to their 1D NMR 
counterparts both for the information on the connection of nuclei and for the 
easier assignment of nuclei resonating in crowded regions of the spectra 
(signal overlapping is much less likely in two dimensions than in one). 
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The COSY (COrrelation SpectroscopY) experiments allow a determination of 
the connectivity of a molecule by revealing which protons are spin-spin 
coupled. In spite of the many modifications which have been proposed along 
the years, the very basic sequence composed of two π/2 pulses separated by 
the evolution period t1 is still the best choice if one is simply dealing with the 
presence or the absence of a given coupling, but not with the value of the 
relevant coupling constant. 
 The HSQC (Heteronuclear Single Quantum Correlation) experiment is 2D 
NMR heteronuclear correlation experiment, in which only one-bond proton-
carbon couplings (1JCH) are observed. The HSQC experiment correlates the 
chemical shift of  proton with the chemical shift of the directly bonded 
carbon.  
The HMBC (Heteronuclear Multiple Bond Correlation) experiment is a 
heteronuclear two-and three-bond 1H-13C correlation experiment; its 
sequence is less efficient than HSQC because the involved 2,3JCH couplings are 
smaller (3-10Hz). Moreover, while 1JCH are all quite close to each other, 2,3JCH 
can be very different, making necessary the optimization of the experiment 
for each type of coupling. As a consequence, in many HMBC spectra not all of 
the correlation peaks which could be expected from the structure of the 
molecule are present. Cross peaks are between protons and carbons that are 
two or three bonds  away while direct one-bond cross-peaks are suppressed. 
This experiment, finally, allow the connection of the fragments and the 
assembling of the structure of the molecules. 
1.2.4 Determination of stereochemistry  
The determination of absolute and relative stereochemistry is a key step for 
the characterization of natural products. The knowledge of the 
stereochemical details of a compound is tightly linked with molecular 
recognition and biological activity. In the human system, enantiomeric drugs 
may give rise to different interactions, thus behaving very differently in their 
activity, toxicology, adsorption, metabolism, pharmacokinetics and 
bioavailability.12 So, the knowledge of the three-dimentional disposition of a 
molecule is important to understand the biological activity, the interaction 
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drug-receptor, but also to synthesize improved analogues of natural 
products. 
Many natural compounds have one or more chiral centers. In the 
configuration determination, establishing the relative configuration of chiral 
centers is usually the first step. NMR can be very useful, especially trough 
evaluation of chemical shifts (δ), coupling constants (J) and NOE effects. The 
chemical shifts of protons are influenced by their chemical surrounding, so 
the protons of two diastereomers have different values. 
The Karplus’s equation13 describes the influence of relative arrangements of 
protons in a molecules on the values of coupling constants (JH-H). 
                                                  3J= Acosθ2 + Bcosθ + C   
This equation evidences that the values of homonuclear (3JH-H) and 
heteronuclear (3JC-H) coupling constants are related to the value of the 
dihedral angle θ between atoms. The superscript "3" indicates that a 1H atom 
is coupled to another 1H atom three bonds away, via H-C-C-H bonds. The 
magnitude of these coupling constants are generally smallest (0-1,5 Hz) 
when the torsion angle is close to 90° and largest at angles of 0 and 180°. In 
some cases the axial-axial coupling constant for an antiperiplanar 180  H-C-C-
H configuration may be more than 9.5 Hz. Indeed for rigid cyclohexanes it is 
around 9-13 Hz, because the dihedral angle is close to 180°, where the 
orbitals overlap most efficiently. 
NOE (Nuclear Overhauser Enhancement) effect14 can give  additional 
information about relative configuration of stereogenic centers. This effect 
can be observed upon irradiation on a specific signal, during the acquisition 
of the spectra: the relaxation times of all the protons surrounding the 
irradiated proton (distance < 2.5 A°), even though not belonging to the same 
spin system, are influenced and thus, their height of signals changes. The NOE 
effect establishes a spatial relationship between substituents of fixed 
molecules, but this effect is dependent from the dimensions of the molecule. 
The ROESY (Rotating-frame Overhauser SpectroscopY) experiment is a 
chemical shift homonuclear correlation which can detect ROEs (Rotating-
frame Overhauser Effect). ROE is similar to NOE, being related to dipolar 
coupling between nuclei, and depending on the geometric distance between 
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the nuclei. While NOE is positive for small molecules and negative for 
macromolecules, ROE is always positive. Therefore, the ROESY experiment is 
particularly useful for mid-size molecules, which would show a NOE close to 
zero. 
The two following sub-paragraph will provide further details about two 
methods used for determination of configuration in this research work. 
1.2.4.1 Murata's Method 
NMR is certainly one of the most powerful instrumental techniques for the 
analysis of the relative stereochemistry of organic compounds. Even more, 
the application of NMR techniques to the problem of determining the relative 
spatial orientation of substituents has became a routine task in modern 
organic chemistry laboratories. 
Cyclic compounds with small (three to six memberered) rings display a 
predicable conformation behavior that allows the knowledge of their 
configuration to be extracted from simple NMR parameters, such as proton-
proton J-coupling values and NOE intensities. A much more challenging task 
is the assignment of relative (and absolute) configuration in the case of 
flexible system, such as open  (polysubstituted) chain and/or macrocyclic 
compounds for which a clear-cut, definite stereochemical strategy is not yet 
available. 
In acyclic systems, all coupling constants are observed as a weighted average 
of each conformer and for this reason, the dihedral angles obtained from 
these data provide a much more reliable constraint information regarding 
the major conformer than NOE data. However, the use of the sole 
homonuclear coupling constants (3JH-H) for relative stereochemistry 
assignments in flexible system is not feasible since they don’t allow to 
distinguish among all the spatial arrangements of the substituents linked to a 
two-carbon fragments, as it would be needed for the identification of the 
rotamer with the correct configuration (Figure 1.3). 
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Figure 1.3 Values of 3JHH coupling for the six staggered rotamers corresponding to 
two different diastereomers erythro and threo 
In other words, even if we restrict our attention just to staggered 
conformations, in absence of additional information on the geometry of the 
system, one angular constraint for each C2 segment is not sufficient to solve 
the problem, since more solutions can be consistent with the experimental 
data. The situation changes dramatically, though, when additional angular 
information on a stereochemically undetermined C2 fragment is provided 
from heteronuclear coupling costant  (2,3JCH). Along these lines, Murata et al.15 
have reported a method for the assignment of the relative configuration of 
acyclic compounds based on the combined use of homonuclear proton-
proton coupling constants 3JH-H, heteronuclear proton-carbon coupling 
constants 2,3JH-C and NOE data. 
This model is basically applicable to acyclic structures having stereogenic 
carbons bearing hydroxyl, alkoxy or methyl substituents. Every chiral 
molecule containing consecutive or alternate streochemical centers can be 
ideally divided in two carbon fragment. This simplification allows the 
determination, for each single fragment, of the predominant rotamer with the 
exact configuration, among the six possible staggered conformers through 
the use of the J-based NMR approach, see Scheme 1.2. For the sake of 
simplicity, let us compare every single couple of vicinal asymmetric carbons 
to those belonging to a 2,3-disubstituted butane system. The strategy 
followed for a 2,3-disubstituted butane can then be applied to a large variety 
of natural and synthetic products in which the substituents are methoxy, 
hydroxy and methyl groups. A 2,3-disubstituted butane can have two relative 
diastereomeric configurations, named syn (or threo) and anti (or erythro). 
Each of these two configurations can be arranged in three staggered 
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rotamers, for a total of six possible conformers, as shown in Scheme 1.2 (A1, 
A2, A3, B1, B2, B3). Every single rotamer shows its own homonuclear and 
heteronuclear coupling constant pattern. Assuming that we have a sufficient 
number of experimental coupling constraints, these 3JH-H and 2,3JC-H will allow 
to univocally identify four of the six rotamers, namely A1, A3, B1, B3. The two 
rotamers A2 and B2, characterized by an anti position of the two vicinal 
protons, have to be distinguished on the basis of NOE (or ROE) data because 
they show the same coupling constant pattern. 
The first step in the determination of the relative configuration of two vicinal 
methines consists in the evaluation of the homonuclear proton-proton 
coupling constant of the C2 fragment of interest (Scheme 1.2), in order to 
assess whether or not it exists in a predominant conformation. 
Small 3JH-H (0-4 Hz) will indicate a gauche arrangement of H2 and H3 protons.  
In this case the relative configuration can be safely obtained from three or 
four additional angular constraints deriving from the heteronuclear coupling 
constants values. These 2,3JC-H values, indeed, will allow to establish the 
arrangement  (gauche or anti) of H2 with regard to substituent Y and C4 and 
the arrangement of H3 with regard to substituent X and C1 and will therefore 
allow to choose the correct gauche rotamer among A1, A3 (threo), B1 and B3 
(erythro) (Schemes 1.2).  
Large 3JH-H values (8-12 Hz) indicate anti disposition of the protons. 
Nevertheless the 2,3JC-H values are the same for both rotamers A2 (threo) and 
B2 (erythro) (Schemes 1.2) and so they don’t allow to distinguish them. In 
this case it is necessary to use NOE data regarding protons on carbons C1 and 
C4 and possibly protons on substituents Y and X. An NOE effect between 
protons on C1 and C4 and/or an NOE effect between protons on Y and X 
suggest the rotamer A2 in Scheme 1.2, while an NOE between protons on C1 
and on Y and/or an NOE between protons on C4 and on X are suggestive of 
the rotamer B2. Intermediate values of 3JH-H (4-8 Hz) are usually indicative of 
an interconversion between two or more conformers that is fast on the NMR 
scale. In this case, it would be still possible to identify the alternating 
conformers on the basis of the homonuclear and heteronuclear coupling 
constant value and to assign the relative configuration, but the methodology 
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is being pushed to the limit and therefore much more care has to be put in its 
application. In addition, the registration of NMR spectra at a low temperature 
can be of help in case of complex conformational equilibria, due to the 
population increase of the most stable conformer. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.2 Identification of the single conformer with a correct configuration from 
the staggered rotamers with threo (syn) and erytro (anti) arrangements through the 
combined use of measured 3JHH and 2,3JCH values. 
For small molecules, the homonuclear 3JH-H can be easily determined through 
the analysis of a 1D proton spectrum. Nevertheless, the use of more 
sophisticated 2D NMR techniques, such as E.COSY16 or P.E.COSY17, is 
mandatory when the direct measurement of the J values in the proton spectra 
of medium and high molecular weight products is prevented by severe signal 
overcrowding. 
Heteronuclear long range 2,3JC-H values have become widely available after the 
introduction of inverse detection NMR techniques18 and the implementation 
of pulse-field-gradient (PFG) hardware in commercial NMR spectrometers. 
These values are determined, in the original method proposed by Murata, by 
2D hetero half-filtered TOCSY (HETLOC),19-20 phase sensitive HMBC (PS-
HMBC)21-22 experiments and, in a recent application of the methodology, 
HSQC-TOCSY spectra have also been used for this purpose. 
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However, the extensive use of JC-H couplings in the analysis of the relative 
configuration has been hampered due to the difficulties arising from the need 
to make reliable judgments on the size (large, medium or small) of a given 
heteronuclear J coupling value in the absence of a desirable wealth of 
literature data and of efficient empirical rules, unlike the case of 1H-1H J 
values, and due to the impossibility to deal with cases in which the dominant 
conformation of the C2 fragment under investigation is represented by an 
anti arrangement between protons. Indeed, in this particular instance, the 
sole pattern, however extensive, of homo- and heteronuclear J-couplings 
does not allow us to distinguish between the two possible relative 
configurations (erythro and threo). 
1.2.4.2 Marfey's Method 
Indirect methods, to determinate the absolute configuration, involve the 
formation of covalent diastereomeric derivates by reacting the enantiomers 
with a chiral derivatizing agent (CDA). Thus the diastereomeric derivatives 
may be resolved by using conventional achiral columns in HPLC, both normal 
and reversed phase. 
The most widely used method to determinate the absolute stereochemistry 
of ribosomial amino acids is the Marfey’s method.23 This method consists of 
the derivatization of amino acid residues, obtained by complete acid 
hydrolysis of peptide, with a chiral agent FDAA (1-fluoro-2,4-dinitrophenyl-
L-alaninamide, Figure 1.4) and then the comparison of retention times of 
these derivates from parent peptide with the retention time of appropriate 
standards D and L through HPLC. 
This method is enough easy for ribosomial amino acids, commercially 
available, and consist of four phases: 
a) Hydrolysis of parent peptide with HCl 6 N; 
b) Derivatization of the hydrolyzed  with L-FDAA; 
c) Derivatization of both standards, D and L, with L-FDAA. It is possible 
to derivatize L-amino acid with D-FDAA, if the D-standard isn’t 
commercially available or is too expensive. 
d) Analysis through HPLC of retention times. 
Chapter 1- Introduction 
19 
 
 
 
 
 
Figure 1.4 Structure of L-FDAA 
However, it is difficult to apply this chromatographic method to a peptide 
containing unusual amino acids without having their standard samples. 
Another limitation is the possibility to make mistake valuing the tR of the 
derivates in HPLC. The last problem can be solved using LC-MS that allowed 
to identify the peak through the m/z ratio. 
Recently a new method was developed, known as “advanced Marfey’s 
method”,24 useful to determinate the absolute configuration of non-
conventional amino acids, not commercially available, and is based on the 
elution time of amino acids derivatized wih L-FDAA. This method was tested 
on a number of proteogenic or not amino acids and showed the L-aminoacid-
L-FDAA is always eluted from the column before its corresponding D-isomer. 
Now it is well recognized, according to the NMR and UV measurement, that 
D- and L-aminoacid-L-FDAA derivatives can be resolved due to the difference 
in their hydrophobicity which is derived from the cis or trans type 
arrangement of two more hydrophobic substituents at both α-carbons of an 
introduced amino acid and L-FDAA; the D-isomer (with a cis type 
arrangement) interacts more strongly with RP silica gel and has the longer 
retention time compared to the less hydrophobic L-amino acid-L-FDAA, 
which has a trans type arrangement (Figure 1.5).  
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Figure 1.5 Structure of D and L aminoacids L-FDAA derivatives. 
The advanced Marfey’s method is an useful tool to determinate the absolute 
configuration of non ribosomial amino acids. It consists of four steps: 
a) The amino acid obtained from hydrolysis of the peptide is divided 
into two portions; 
b) Derivatization of amino acid with L-FDAA; 
c) Derivatization of amino acid with D-FDAA; 
d) Analysis of tR through LC-MS. 
The peaks of any amino acids in peptides are identified without a standard 
sample using mass spectrometry, and the absolute configuration of a desired 
amino acid is deduced from its corresponding enantiomer.  
This method is applicable to determinate the absolute configuration of the  
chiral center of -amino acid and to determine the absolute configuration of 
-amino acid with more chiral centers, only if the relative configuaration is 
known. 
The method cannot be used for β or -aminoacids and for aminoacids with 
more chiral centers, if it the relative configuration is  unknown. 
The advanced Marfey’s method is a nonempirical one, but it has some draw-
backs, since it relies on the eluition order of amino acid derivative with L-
FDAA to determine its absolute configuration. It is clear that the nature of the 
amino acid side-chain is responsible for this behavior. So, some aminoacids 
do not follow the eluition order in column and the isomer L-amino acid-L-
FDAA has a longer ritention time compared to the D-amino acid-L-FDAA, or 
the two derivatives have tR too similar. The aminoacids with ionizable side-
chain, like Asp and Glu, pose problems of derivatization. Amino acids like 
tyrosine and histidine or containing two amino groups such as ornithine and 
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lysine can form both mono- and di-substituted Marfey’s derivatives thus 
doubling the number of peaks in a chromatogram for these amino acids. 
1.2.5 General Experimental Section  
Optical rotations (CHCl3) were measured at 589 nm on a P2000 Jasco 
polarimeter or Perkin–Elmer 243 B polarimeter.  NMR spectra were obtained 
on Varian Inova 700 MHz, 500 MHz and 400 MHz spectrometer (1H at 700 
MHz, 13C at 175 MHz) equipped with a Sun hardware, or on Bruker Avance 
3HD 400 or 600 (USA), J in Hz, spectra referred to CD3OD (δH = 3.32, δC  = 
55.0) or CDCl3 (δH = 7.26, δC = 77.0)  or DMSO (δH = 2.50, δC = 39.5) as internal 
standard. Homonuclear 1H connectivities were determined by the COSY 
experiment. One-bond heteronuclear 1H-13C connectivities were determined 
with the HSQC experiment. Through-space 1H connectivities were evidenced 
using a ROESY experiment with a mixing time of 250 ms. Two and three bond 
1H-13C connectivities were determined by gradient 2D HMBC experiments 
optimized for a 2,3J = 9 Hz. The phase sensitive (PS)-HMBC spectra were 
recorded with the delay set at 40 ms and a data size of 2K (F2)  128 (F1) 
points. Low- and high-resolution ESIMS spectra were obtained on a LTQ 
OrbitrapXL (Thermo Scientific) mass spectrometer. Medium pressure liquid 
chromatography was performed on a Büchi apparatus using a silica gel (230-
400 mesh) column; silica gel 60 (70-230 mesh) and RP-18 used for gravity 
column chromatography was purchased from Macherey-Nagel. Flash 
chromatographies were performed with a Buchi C615/601 pump system 
using silica gel cartridges (40-63 µm) (Buchi®, Swintzerland). Preparative 
HPLC were performed on a LaChrom-Merck Hitachi HPLC system, pump L-
7100, UV detector L-7400 using a C-18 column (Knauer, 300 x 8 mm, 
prefilled with C-18 Eurosphere, flow rate 5 mL/min, UV detection at 280 nm). 
Analytic HPLC were achieved on a Knauer apparatus equipped with a 
refractive index detector or on an Alliance apparatus (model 2695, Waters, 
USA) equipped with photodiode array detector (model 2998, Waters), an 
evaporative light-scattering detector (model Sedex 80, Sedere, France) and 
the software Empower; LUNA (Phenomenex, normal phase, SI60, 250 × 4 
mm), LUNA (Phenomenex, C-18, 100-5, 250 x 4.5 mm), GEMINI 
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(Phenomenex, C6-Phenyl, 5 µm, 250 x 4.6 mm) columns were used, with 0.7 
or 1 mL/min as flow rate. 
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CHAPTER 2 -BIOACTIVE MACROLIDES, DEPSI-
PEPTIDES AND STEROLS FROM THE SPONGE 
THEONELLA SWINHOEI 
A substantial part of the research work during my PhD involved chimical 
analysis of marine invertebrates, particularly sponges, very rich sources of 
secondary metabolites. Sponges Theonella swinhoei and Iotrochota purpurea 
have been the object of my study. 
2.1 PORIFERA: A TREASURE TROVE OF SECONDARY 
METABOLITES 
Sponges (phylum Porifera) are the most primitive of the multicellular 
animals. Neither true tissues nor organs are present and the cells display a 
considerable degree of independence. All the members of the phylum are 
sessile and exhibit little detectable movement.  
Sponges are aquatic sessile filter feeders and live permanently attached to a 
location in the water. Sponges can be found in nearly all aquatic environment 
(marine and fresh water; shallow and deep; tropical and Antarctic), wherever 
there are substrata for sponge attachment and growth.1 
They can show a variety of sizes, colors, and shapes, including arboresecent 
(tree-like), flabellate (fan-shaped), caliculate (cup shaped), tubular (tube 
shaped) and amorphous (shapeless) (Figure 2.1).  
 
 
 
Figure 2.1 Some examples of Porifera. 
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The outer dermal membrane is composed of two cell layers of specialized 
cells named pynacocytes, which digest food particles too large to enter the 
ostia. The body wall is approximately two cell layers thick with a gel like 
substance named mesohyl, the gelatinous matrix within the sponge made of 
collagen. The body wall is perforated by many pores and channels (ostia), 
through which water enters the animal, passing into the spongocoel, and 
exiting it through a large opening, the osculum (Figure 2.2). The interior 
cells are called choanocytes and contain a central flagellum surrounded by a 
collar of microvilli which are connected by a thin membrane. By 
cooperatively moving their flagella, choanocytes generate a flow of water 
through the sponges pores, into the spongocoel, and out through the 
osculum. This improves both respiratory and digestive functions for the 
sponge, pulling in oxygen and nutrients and allowing a rapid expulsion of 
carbon dioxide and other waste products. 
 
        Figure 2.2  A sponge body structure. 
Body plans range from simple through to complex, produced by varying 
degrees of infolding of the body wall and complexity of water canals 
throughout the sponge. The simplest body structure in sponges is a tube or 
vase shape known as asconoid. This refers to a sessile tubular structure. 
Water, along with particulate matter, flows through small pores. The ostia 
lead to flagellated coanoderm which pick up particulate matter, while the 
water is pushed up and out of the tube at the osculum.  
Syncanoids also take on tubular structure but have an internal tissue which 
generates a much greater surface area for the absorption of nutrients. Folds 
in the internal tissue create a sort of zigzag pattern in which the internal 
openings are referred to as choanocyte chambers. The external openings are 
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incurrent canals. The body of the sponges is reinforced by the skeleton, 
collagen fibers and spicules (Figure 2.3). Sponges use various materials to 
reinforce their mesohyl and in some cases to produce skeletons and this form 
the main basis for classifying sponges.  
 
Figure 2.3 Microscope image of spicules. 
Demosponges reinforce the mesohyl with fibers of a special form of collagen 
called spongin, most also produce spicules of silica, and a few secrete massive 
external frameworks of calcium carbonate. Although glass sponges also 
produce spicules made of silica, their bodies mainly consist of syncytia that in 
some ways behave like many cells sharing a single external membrane, and in 
others like individual cells with multiple nuclei.  
Demosponges constitute about 90% of all known sponge species, including 
all freshwater ones, and have the widest range of habitats.  
Sponges, lacking any physical defence from their predators, rely on chemical 
defense mediated by secondary metabolites, which are essential for their 
survival. The chemicals also probably play a role in competition among 
sponges and other organisms, as they are released by sponges to ensure 
themselves space in the marine ecosystem.  
Sponges are very fertile host animals for diverse symbiotic microorganisms: 
the symbionts locate both intra- and extra cellularly (Figure 2.4), and each 
symbiotic microorganism seems to have a specific habitat in the host sponge. 
Extracellular symbionts are present on the outer layers of sponges as 
exosymbionts, or in the mesohyl as endosymbionts. Intracellular or 
intranuclear symbionts permanently reside in host cells or nuclei.  
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Figure 2.4 Schematic diagram of symbiotic relationships between sponges and 
microorganisms. A, extracellular exosymbiosis; B, extracellular endosymbiosis; C, 
intracellular symbiosis; and D, intranuclear symbiosis. 
A number of promising compounds have been identified from marine 
sponges that possess pronounced biological activity and are already at 
advanced stages of clinical trials, mostly for the treatment of cancer, or have 
been selected as promising candidates for extended preclinical evaluation.2 
The types of compounds characterized from marine organisms are diverse 
and represent many different classes, structurally complex with unique 
functionalities, including cyclic peptides, terpenes and steroids, and 
macrolides. 
Cyclic Peptides are polypeptide chains whose amino and carboxyl terminus 
are themselves linked together with a peptide bond that forms a circular 
chain. The unusual properties of cyclic peptides are due both to their circular 
structure and their unusual mode of biosynthesis, which frequently 
incorporates uncommon amino acids. As result, the presence of non-
ribosomial amino acids produces pronounced effects on the pharmacological 
activities of these metabolites. For example, N-alkylation and the lack of N 
and C termini enhance the hydrophobicity, thus determining a more facile 
crossing of biological membranes and an improved stability to enzymatic 
degradation. Cyclization reduces peptide conformational flexibility that 
results in a higher receptor affinity. All these features make cyclopeptides 
promising lead compounds in drug discovery.  
Cyclic depsipeptides are cyclic peptides in which one or more of the peptide 
(amide) bonds are replaced by other bonds. Other functional groups, 
different from the usual amino and carboxyl group, are linked together, 
closing the polypeptide chain, including ester, lactone, thioester bonds. 
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The biosynthesis of natural cyclic peptides is interesting to biologists, since it 
frequently involves non-ribosomal peptide synthetases. Most peptides are 
made by bacteria. Nonribosomal peptide synthetases (NRPSs) and polyketide 
synthases (PKSs) are multi-enzymatic, multi-domain megasynthases involved 
in the biosynthesis of nonribosomal peptides and polyketides.3-4-5 
Terpenes and steroids are a large and varied class of natural compounds, 
structurally different each other. They derive from C5 isoprene units linked 
together head to tail. Several modes of cyclization are conceivable and lead to 
various skeletons just like the cyclization of polyketide chains. The terpenes 
are classified according to the number of C5 units: monoterpenes, C10; 
sesquiterpenes C15; diterpenes, C20; sesterterpenes, C25; triterpenes, C30; 
and tetraterpenes C40.  The prominent biological activity of marine terpenes 
is evident in their ecological role in the marine environment, and makes them 
interesting as potential drugs. Steroids are terpenes having a tetracyclic ring 
system and comprise a large number of ubiquitous compounds which are 
divided into subgroups, mainly according to side chain functionality: sterols, 
sapogenins, cardiac aglycones, bile acids, adrenal steroids and sex hormones. 
Sterols isolated from sponges are sometimes very complex mixtures of highly 
functionalized compounds, many of which have no terrestrial counterpart.  
Macrolides are a group of compounds that stems from the presence of a 
macrolide ring, usually a large macrocyclic lactone ring to which one or more 
sugars may be attached. Marine macrolides provide a fascinating range of 
structural and functional diversity, which may find application as specific 
molecular probes for the investigation of the cytoskeleton and cell cycle 
events. In fact, many macrolides isolated from sponges disrupt the 
organization of microfilaments, interacting with actin in the cell cytoskeleton, 
and represent a promising mechanism of action for developing novel 
anticancer drugs. 
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2.2 THEONELLA SWINHOEI 
Sponges of the order Lithistida are an evolutionary ancient lineage that is 
typically found in deeper waters and caves of tropical oceans. Lithistid sponges 
have a structurally massive, rigid or “rock-like” morphology. This polyphyletic 
order is grouped together because their skeletons consist of fused or 
interlocked spicules, colled desmas.  
 
Figure 2.5 A specimen of the sponge Theonella sp. collected in the area of Bunaken 
Marine Park of Manado (Indonesia). 
Over half of the compounds reported for lithistid sponges were isolated from 
Theonella (family Theonellidae). Theonella species have been reported to 
contain a wide variety of diverse secondary metabolites with intriguing 
structures and promising biological activities, which have been calculated to 
represent more than nine biosynthetic classes6 (Figure 2.6). In particular, 
Theonella swinhoei represents one of the most prolific source of innovative and 
bioactive metabolites. More than one hundred metabolites have been reported 
from the single extraordinary prolific species Theonella swinhoei, including 
non-ribosomal polypeptides/depsipeptides, polyketide macrolides (as the 
cytotoxic swinholide A, 17), polyene derivatives (exemplified by 
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aurantosides8), and uncommon steroids (4-methylene steroids9 and truncated 
side-chain sulfated steroids10), recently demonstrated to act as modulator of 
nuclear receptors FXR and PXR.11 
 
 
Figure 2.6 Some molecules from Theonella swinhoei. 
Hovewer, among bioactive metabolites found from worldwide collections of 
Theonella swinhoei, surely the peptides represent the most significant group. 
The diverse array of Theonella derived peptides range from acyclic peptides 
such as polytheonamides12, koshikamides A1 and A213-14; cyclic peptides, 
exemplified by cyclotheonamides15-16, kombamide17, orbiculamide18, 
keramamides19, cupolamide20, oriamide21, perthamides22 and 
solomonamides23, large-ring bicyclic peptides, such as theonellamides; 
depsipetides headed by theonellapeptolides24; and glycopeptides25.  As for 
other peptides of marine origin, the most striking feature of these metabolites 
is the preponderance of non-ribosomial amino acids, including the D 
configured, N-methylated and alkylated. 
The exceptional chemical diversity found in the metabolites of Theonella 
sponges may in part be due to the biosynthetic capacity of bacteria that they 
host26. This hypothesis has been convincingly supported in the case of 
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swinholide A, omnamides and theopederins. In 2005, Gerwich27 reported the 
direct isolation of swinholide A and related derivatives from two different 
cyanobacteria, demonstrating that marine cyanobacteria possess the 
metabolic capacity to produce this skeletal class. As concerning omnamides 
and theopederins, from the highly complex metagenome of Theonella swinhoei, 
was identified a prokaryotic gene cluster28, likely responsible for the 
biosynthesis of these two metabolites.29 A bacterial family, named 
Entotheonella sp., has been identified  through single-cell- and metagenomics-
based discovery as the responsible for most of the biosynthetic work 
producing the typical Theonella metabolites.30  
The existence of some different chemotypes of T. swinhoei has been 
postulated7, but a detailed understanding of the genetic bases for the observed 
chemical variation is made problematic by the complexity of the microbial 
community associated with this sponge31.  
In the course of a project directed to the chemical investigation and evaluation 
of the marine invertebrates from Indonesian Sea, in collaboration with the Sam 
Ratulangi University (Manado, Indonesia), my research group had previously 
analyzed a red/yellow specimen of T. swinhoei collected in North Sulawesi 
(Indonesia) which proved to be rich in aurantosides32 and 4-methylene 
steroids,33 while polyketide macrolides and peptide-based derivatives were 
extremely rare if not absent. During Ph.D. period, chemical analysis of a 
brown-colored specimen of T. swinhoei, collected in the same area of the 
previous, has been undertaken, and an extremely different secondary 
metabolite composition was detected. The analysis of this sponge afforded to 
the isolation of new compounds, belonging to different chemical classes. The 
variety of compounds isolated reaffirms the biological richness of Theonella 
swinhoei, that may be considered a cornucopia of metabolites. 
2.3 ISOLATION AND PURIFICATION 
Theonella swinhoei (order Lithistida, family Theonellidae) was collected in the 
Bunaken Marine Park of Manado (North Sualwesi, Indonesia) in January 2010 
and frozen immediately after collection. The frozen material was repeatedly 
extracted with methanol and the crude extract was subjected to a modified 
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Kupchan’s partitioning procedure to obtain n-hexane, CHCl3 and n-BuOH 
extracts. 
The CHCl3 extract was chromatographed by silica gel MPLC; fractions from 
MPLC were further purified by HPLC on reversed-phase column. The study of 
chloroform extract afforded the known swinholides A (1), B (2), D (3) and 
isoswinholide A (4), along with two new members of this family, named 
isoswinholide B (5) and swinholide K (6); the known theonellapeptolide Id (7) 
and the new analogues sulfinyltheonellapeptolide (8) and theonellapeptolide 
If (9); four already known (12-15) and one new compound (16) belonging to 
the 4-methylensterols family. 
2.4 MACROLIDES FROM THEONELLA SWINHOEI 
The known swinholides A (1), B (2), D (3) and isoswinholide A (4), along 
with two new members of this family, named isoswinholide B (5) and 
swinholide K (6) were obtained. The known compounds were identified on 
the basis of the identity of their spectroscopic data with those published in 
the literature.34-35-36 
The whole series of compounds was evalueted on HepG2 cells 
(hepatocarcinoma cell line), revealing that the new swinholide K (6) is a 
potent cytotoxin, while isoswinholide B (5) is at least 100 times less active 
than its parent compound 1. 
Isoswinholide B (5) was isolated as an optically active white powder for 
which HR-ESIMS indicated the molecular formula C78H132O20, identical to that 
of the parent compound swinholide A (1). The 1H NMR profile of 5 (CD3OD, 
Table 2.1) soon suggested its belonging to the swinholide family; however, 
the marked splitting of many signals was indicative of a lack of symmetry 
between the two C39 units of the dilactone system. In swinholides B,31 C,31 D7 
and G7 this effect is due to methylation or demethylation at a single center, 
while in swinholides E,7 I37 and J30 it is ascribable to the presence of an 
additional oxygen atom on the carbon backbone. Both these kinds of 
structural changes should be excluded in the case of 5 on the basis of 
molecular formula consideration; in addition, an inspection of the 1H NMR 
spectrum aided by the 2D HSQC experiment revealed that all the expected 
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methyl groups (four linking oxygen, ten linking sp3 methines and two linking 
sp2 unprotonated carbons) were actually present in the structure of 5.   
 
 
Careful inspection of 2D COSY and TOCSY spectra of 5 allowed the definition 
of two large spin systems (from H-5 to 31-Me and from H-5’ to 31’-Me), 
extended to H-2/2’ and H-3/3’ on the basis of the long-range couplings 
showed by 4-Me/4’-Me (Table 2.1), thus defining a backbone identical to 
that of swinholide A, including the trans geometry of the disubstituted double 
bond (JH-2/H-3 = JH-2’/H-3’ = 15.9 Hz). 
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As evidenced by the careful comparison of the proton resonances assigned 
for 5 with those reported for swinholide A (1),30 the main differences lie in 
the dienoate region of one unit and in the H-17/H-23 region of the other unit 
(Figure 2.7). On the contrary, as for swinholide A, proton resonances and 
coupling constants from position 25 to position 31 were practically identical 
for the two units, indirectly suggesting that these regions should not be 
involved in the loss of symmetry.  
 
 
Figure 2.7 Comparison between the resonances of isoswinholide B (5) and 
swinholide A (1) in selected regions. Δδ (isoswinholide B – swinholide A) is reported 
in ppm 
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Table 2.1 1H (700 MHz) and 13C (175 MHz) NMR data of  isoswinholide B (5) in CD3OD 
 
 
Extensive analysis of HSQC and HMBC spectra allowed the assignment of all 
the carbon resonances of 5 (Table 2.1) and the definitive confirmation of the 
structure of the two C39 halves, both identical to that of the symmetric 
swinholide A. This implied that compound 5 should differ from 1 only in one 
or both the lactonization positions. The HMBC cross-peaks H-21/C-1’ and H-
19’/C-1 unambiguously identified the oxygens at C-19’ and C-21 as those 
Pos. δH mult (J in Hz) δC (type) Pos. 
 
δH (J in Hz) δC (type) 
1 - 169.4 (C) 1’ - 170.3 (C) 
2 5.86 d (15.9) 115.0 (CH) 2’ 5.89 d (15.9) 115.0 (CH) 
3 7.36 d (15.9) 149.9 (CH) 3’ 7.44 d (15.9) 149.9 (CH) 
4 - 135.1 (C) 4’ - 135.1 (C) 
4-Me 1.80 s 11.4 (CH3) 4’-Me 1.80 s 11.4 (CH3) 
5 6.06 t (7.0) 139.3 (CH) 5’ 6.18 t (6.8) 139.1 (CH) 
6 2.38 ovl 37.5 (CH2) 6’ 2.43 ovl 37.5 (CH2) 
7 4.00 ovl 67.2 (CH) 7’ 4.11 m 66.7 (CH) 
8 1.37 m, 1.75 m 40.0 (CH2) 8’ 1.33 m, 1.76 m 40.0 (CH2) 
9 4.47 ovl 69.1 (CH) 9’ 4.47 ovl 69.1 (CH) 
10 5.66 ovl 129.8 (CH) 10’ 5.66 ovl 129. 8 (CH) 
11 5.82 m 123.6 (CH) 11’ 5.82 m 123.6 (CH) 
12 1.96 m 31.6 (CH2) 12’ 2.01 m 31.1 (CH2) 
13 3.55 m 63.9 (CH) 13’ 3.60 m 64.4 (CH) 
14 1.57 m, 1.83 m 37.2 (CH2) 14’ 1.59 m/1.87 m 35.7 (CH2) 
15 3.77 m 78.1 (CH) 15’ 3.79 m 77.3 (CH) 
15-OMe 3.33 s 55.8 (CH3) 15’-OMe 3.35 s 55.8 (CH3) 
16 1.53 m 43.9 (CH) 16’ 1.59 m 41.9 (CH) 
16-Me 0.84 d (7.0) 8.4 (CH3) 16’-Me 0.85 d (6.8) 8.4 (CH3) 
17 3.62 m 73.1 (CH) 17’ 3.61 m 69.8 (CH) 
18 1.60 m, 1.76 m 39.1 (CH2) 18’ 1.83 m, 1.88 m 38.3 (CH2) 
19 3.99 ovl 71.9 (CH) 19’ 5.65 m 74.2 (CH) 
20 1.91 m 39.3 (CH) 20’ 1.98 m 36.9 (CH) 
20-Me 0.91 d (7.0) 13.2 (CH3)  20’-Me 0.94 d (7.0) 8.6 (CH3) 
21 5.40 m 75.1 (CH) 21’ 3.64 m 73.0 (CH) 
22 1.93 m 37.7 (CH) 22’ 1.85 m 37.9 (CH) 
22-Me 0.94 d (7.0) 8.8 (CH3) 22’-Me 0.95 d (7.0) 8.8 (CH3) 
23 3.12 dd (2.0, 9.7) 76.2 (CH) 23’ 3.36 ovl 78.2 (CH) 
24 1.73 m 34.6 (CH) 24’ 1.67 m 33.0 (CH) 
24-Me 0.98 d (6.5) 16.7 (CH3) 24’-Me 0.93 d (6.5) 16.1 (CH3) 
25 1.28 m, 1.42 m 24.2 (CH2) 25’ 1.28 m,1.42 m 24.2 (CH2) 
26 1.30 m, 1.94 m 29.0 (CH2) 26’ 1.30 m, 1.94 m 29.0 (CH2) 
27 3.97 ovl  72.4 (CH) 27’ 3.97 ovl  72.4 (CH) 
28 1.53 m, 1.87 m 35.7 (CH2) 28’ 1.53 m, 1.87 m 35.7 (CH2) 
29 3.63 m 74.1 (CH) 29’ 3.63 m 74.1 (CH) 
29-OMe 3.34 s 54.2 (CH3) 29’-OMe 3.34 s 54.2 (CH3) 
30  1.11 ovl, 1.91 ovl 39.5 (CH2) 30’  1.11 ovl, 1.91 ovl 39.5 (CH2) 
31 3.76 m 65.7 (CH) 31’ 3.76 m 65.7 (CH) 
31-Me 1.19 d (6.1) 20.8 (CH3) 31’-Me 1.19 d (6.1) 20.8 (CH3) 
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involved in the formation of the two lactone functionalities. Thus, compound 
5 is a new member of the swinholide family, named isoswinholide B, showing 
the unprecedented 21/19’ lactonization pattern. The single isoswinholide 
known before was isoswinholide A (4), showing lactonization at O-21 and O-
23’. Interestingly, acidic treatment of swinholide A with p-TsOH afforded the 
symmetric 23/23’-diolide and 19,19’ diolide, and the desymmetrized 23,17’-
diolide, but no traces of isoswinholide B were detected.38 On the other hand, 
we found no traces of the above synthetic isoswinholides in our specimen of 
T. swinhoei. 
Swinholide K (6) was isolated as a white powder with molecular formula 
C78H132O21, one oxygen atom more than swinholide A, as indicated by HR-
ESIMS. Inspection of the 1H NMR spectrum of 6 (Table 2.2), clearly revealed 
that this compound, similarly to 5, experienced a loss of symmetry of the two 
C39 units, which could be, most likely, ascribed to the presence of the 
additional oxygen atom in one of the two units. In particular, the 1H NMR 
spectrum of 6 showed thirteen resonances in the region 5.43-7.43 ppm in 
place of the resonances for six pairs of equivalent protons as in 1. Moreover, 
in contrast to 1, the 1H NMR spectrum of 6 exhibited an additional resonance 
in the midfield region of the spectrum (δH 4.62, m), while it clearly lacked of 
one of the two allylic methyl groups attached at positions 4/4’. COSY and 
TOCSY spectra of 6 allowed us to build up its proton spin systems which, for 
resonances assigned to positions from 9 to 31, appeared perfectly symmetric 
and superimposable to values reported for swinholide A.30 These data clearly 
suggested that a perturbation in the dienoate region at one half of the 
molecule had occurred.  
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The 13C NMR spectrum of 6 (Table 2.2), interpreted with the help of HSQC 
and HMBC experiments, concurred in suggesting a perturbation in one of the 
C-1 to C-8 moieties and a perfect symmetry in the remaining parts of the 
molecule. In particular, the 13C NMR spectrum showed twelve resonances in 
the double bond region (seven methines, two of which assignable to the two 
pairs of equivalent carbons C-10/C-10’ and C-11/C-11’, one methylene and 
four unprotonated carbons, including the two ester carbonyl resonances) in 
place of the seven signals showed by the symmetric swinholide A in the same 
region. Extensive analysis of COSY, HSQC and HMBC spectra allowed us to 
define the structures of the two C-1 to C-8 moieties, one of which was 
established to be identical to that of swinholide A. In the other moiety, the 
trans (JH-2/H-3’ = 16.2 Hz) double bond C-2/C-3 should be conjugated with 
an unprecedented C-4/4-CH2 double bond, as indicated by the HMBC 
correlations of the sp2 methylene protons with C-3 and C-4 (Figure 5). The 
additional oxygen atom implied by molecular formula was placed at C-5 on 
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the basis of the HMBC correlation of 4-CH2 with an oxymethine resonating at 
δC 70.0 (Figure 2.8), thus defining the structure of swinholide K (6).  
 
 
Figure 2.8 Key COSY and HMBC correlation detected for the C-1/C-8 moiety of 
swinholide K (6) 
Swinholide K (6) includes an additional stereogenic oxymethine at C-5 and 
we decided to undertake the elucidation of its configuration. Since the 1H/1H 
coupling constant pattern exhibited by H-5, H-6a and H-6b (Table 2.2) was 
strongly suggestive of the existence of a predominant staggered rotamer 
around the C-5/C-6 and C-6/C-7 axes, we deemed possible the application of 
the Murata’s J-based configuration analysis39 to solve this stereochemical 
problem.  
 
OH
3J (H-5/H-6a) = large
3J (H-5/H-6b) = small
3J (H-5/C-7)   = small
2J (C-5/H-6b) = small
2J (C-5/H-6a) = large
H-6b
C-5
H-5
C-4
C-7
H-6a
3J (C-4/H-6b) = small
3J (C-4/H-6a) = small
OH
3J (H-7/H-6a) = large
3J (H-7/H-6b) = small
3J (H-7/C-5)   = small
2J (C-7/H-6b) = small
2J (C-7/H-6a) = large
H-6b
C-7
H-7
C-8
C-5
H-6a
3J (C-8/H-6b) = small
3J (C-8/H-6a) = small
 
Figure 2.9 Application of the Murata’s method to the C-5/C-6 and C-6/C-7 bonds of 
swinholide K (6) 
This NMR-based method allows elucidation of relative configuration in acyclic 
structures basing on 3JH,H and 2,3JC,H values. In our case, the required 
homonuclear coupling constants could be measured from the 1H NMR 
spectrum (Table 2.2), while the heteronuclear coupling constants were 
qualitatively evaluated through careful analysis of the phase sensitive (PS)-
HMBC spectrum (Fig. 2.9). 
The obtained pattern of J values appeared perfectly consistent in indicating a 
C-5/C-7 erythro stereochemical relationship. Thus, on the basis of the known 
configuration at C-7, we could assign the R configuration at C-5, 
unambiguously defining the stereostructure of swinholide K (6). This is a new 
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member of the small family of swinholide derivatives showing a structural 
modification in one or both the dienoate moieties, a family including only  
bistheonellides (also known as misakinolides),40 hurghadolide,33 swinholides F 
(2Z isomer of swinholide A)32 and J (4,5-epoxy swinholide A).26  
 
Table 2.2 1H (700 MHz) and 13C (175 MHz) NMR data of  swinholide K (6) in CD3OD. 
Pos. δH mult (J in Hz) δC (type) Pos. δH (J in Hz) δC (type) 
1 - 169.4 (C) 1’ - 170.3 (C) 
2 6.17 d (16.2) 119.3 (CH) 2’ 5.89 d (15.7) 115.8 (CH) 
3 7.33 d (16.2) 145.5 (CH) 3’ 7.43 d (15.7) 150.9 (CH) 
4 - 149.5 (C) 4’ - 135.4 (C) 
4-CH2 5.60 br s, 5.45 br s 121.6 (CH2) 4’-Me 1.80, s 11.4 (CH3) 
5 4.62 dd (8.2, 2.9)   70.5 (CH) 5’ 6.14 t (6.8) 139.1 (CH) 
6 1.62 dt (11.2, 2.9)  
1.82 dt (11.2, 8.2) 
  36.9 (CH2) 6’ 2.43 m   37.5 (CH2) 
7 3.98 ovl   69.9 (CH) 7’ 4.03 m   67.7 (CH) 
8 1.77 m, 1.36 m   41.0 (CH2) 8’ 1.76 m, 1.31 m   40.0 (CH2) 
9 4.49 brd (10.5)   69.1 (CH) 9’ 4.49 brd (10.5)   69.1 (CH) 
10 5.68 dd (1.8, 10.5) 129.9 (CH) 10’ 5.68 dd (1.8, 10.5) 129. 8 (CH) 
11 5.83 m 123.9 (CH) 11’ 5.83 m 123.9 (CH) 
12 1.98 m   31.6 (CH2) 12’ 1.98 m   31.1 (CH2) 
13 3.57 ovl   63.9 (CH) 13’ 3.57 ovl   64.4 (CH) 
14 1.58 m, 1.75 m   37.5 (CH2) 14’ 1.58 m, 1.75 m   35.7 (CH2) 
15 3.75 m   77.5 (CH) 15’ 3.75 m   77.4 (CH) 
15-OMe 3.35 s   55.8 (CH3) 15’-OMe 3.35 s   55.8 (CH3) 
16 1.52 m   43.9 (CH) 16’ 1.52 m   43.9 (CH) 
16-Me 0.85 d (6.7)     8.5 (CH3) 16’-Me 0.85 d (6.7)     8.4 (CH3) 
17 3.61 ovl   73.1 (CH) 17’ 3.61 ovl   72.8 (CH) 
18 1.65 m, 1.75 m   39.1 (CH2) 18’ 1.65 m, 1.75 m   39.3 (CH2) 
19 3.97 ovl   71.9 (CH) 19’ 3.97 ovl   71.9 (CH) 
20 1.94 m   39.3 (CH) 20’ 1.94 m   39.3 (CH) 
20-Me 0.91 d (7.0)     9.2 (CH3)  20’-Me 0.91 d (7.0)     8.6 (CH3) 
21 5.43 ovl   74.7 (CH) 21’ 5.45 ovl   74.7 (CH) 
22 1.98 m   37.7 (CH) 22’ 1.98 m   37.9 (CH) 
22-Me 0.94 d (7.0)    8.8 (CH3) 22’-Me 0.94 d (7.0)     8.8 (CH3) 
23 3.12 dd (1.8, 9.5)   76.5 (CH) 23’ 3.12 dd (1.8, 9.5)   76.5 (CH) 
24 1.70 m   34.6 (CH) 24’ 1.70 m   34.6 (CH) 
24-Me 0.98 d (6.8)   16.7 (CH3) 24’-Me 0.98 d (6.8)   16.6 (CH3) 
25 1.24 ovl, 1.42 m   24.2 (CH2) 25’ 1.24 ovl, 1.42 m   24.2 (CH2) 
26 1.28 ovl, 1.95 m   29.0 (CH2) 26’ 1.28 ovl, 1.95 m   29.0 (CH2) 
27 3.99 ovl   72.7 (CH) 27’ 3.99 ovl   72.4 (CH) 
28 1.52 m, 1.88 m   35.7 (CH2) 28’ 1.52 m, 1.88 m   35.7 (CH2) 
29 3.62 m   74.3 (CH) 29’ 3.62 m   74.1 (CH) 
29-OMe 3.35 s   54.2 (CH3) 29’-OMe 3.35 s   54.2 (CH3) 
30 1.10 dd (10.4, 
12.8),  
2.03 br d (12.8) 
  39.6 (CH2) 30’ 1.10 dd (10.4, 
12.8),  
2.03 br d (12.8) 
  39.5 (CH2) 
31 3.74 m   65.7 (CH) 31’ 3.74 m   65.7 (CH) 
31-Me 1.20 d (6.3)   20.8 (CH3) 31’-Me 1.20 d (6.3)   20.8 (CH3) 
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2.5 DEPSIPEPTIDES FROM THEONELLA SWINHOEI 
Pursuing the study of the chloroform extract of Theonella swinhoei, two new 
cyclic tridecadepsipeptide of the theonellapeptolide family were isolated:  
sulfiniltheonellapeptolide (8), characterized by a methylsulfinylacetyl group 
at the N-terminus, and theonellapeptolide If (9), the first member of this class 
of compounds to show four valine residues. The structures of the compounds, 
isolated along with the known theonellapeptolide Id (7), were determined by 
extensive 2D NMR and MS/MS analyses followed by application of Marfey’s 
method41. The isolated peptides exhibited moderate antiproliferative activity 
against HepG2 cells, a hepatic carcinoma cell line. 
 
Theonellapeptolides are tridecapeptide lactones characterized by the 
presence of aliphatic and non-polar amino acids including high ratio of D-
amino acids, N-methyl amino acids, and β-amino acids. In particular, the 
structure of theonellapeptolide Id (7) includes three β-Ala, three D-Leu (one 
N-methylated), two L-Val (one N-methylated), one L-MeAla, one L-Thr, one L-
MeIle, and two D-alloIle (one N-methylated) units. 
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Sulfinyltheonellapeptolide (8, [α]D −38.1, c 0.1, MeOH) was isolated as a 
colorless amorphous solid with pseudomolecular ion peaks at m/z 1423 [M + 
H]+ and 1445 [M+Na]+ in the ESIMS, and high-resolution analysis established 
the molecular formula C69H123N13O16S. Inspection of its 1H NMR spectrum 
(CD3OD, Table 2.3) clearly suggested the peptide nature of 8 and placed it 
into the theonellapeptolide class. Given this characterization of 8 the 
presence of the sulfur atom in the molecular formula appeared especially 
remarkable. In particular, the 1H and 13C NMR data of 8 indicated the 
presence of six methyl singlets (δH 2.77, 2.79, 3.22, 3.30, 3.31, and 3.35) and 
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fourteen carbonyl groups (resonating from δC 166.5 to 177.0). Extensive 
analysis of homonuclear and heteronuclear 2D NMR spectra including 1H/1H 
COSY, 1H/1H TOCSY, 1H /13C HSQC and 1H /13C HMBC allowed to overcome 
the difficulty posed by the severe signal overlap in the 1H NMR spectrum and 
to establish the presence of three β-Ala, three Leu (one N-methylated), two 
Ile (both N-methylated), three Val (one N-methylated), one Thr, and one N-
methylAla, the same amino acid composition as in theonellapeptolide Id (7) 
except for one residue. The above analysis left unassigned a methyl singlet at 
δH 2.79 (δC 39.2) and a pair of mutually coupled doublets at δH 3.67 and 3.86, 
with these latter signals showing HMBC correlations both with the methyl 
carbon at δC 39.2 and an amide carbonyl resonating at δC 166.5. The 1H and 
13C NMR chemical shift values of both the methyl and the methylene groups 
strongly suggested their linkage to a sulfoxide group, and the presence of a 
methylsulfinylacetyl (MeS(O)Ac) subunit was also in full agreement with the 
molecular formula. The amino acid sequence of 8 was then disclosed by 
careful analysis of the pattern of HMBC correlations, whose key cross-peaks 
are shown in Figure 2.10. The cross-peak of the Thr low-field shifted β-CH 
(δH 5.19) with the Me-Ile carbonyl group revealed the presence of an ester 
linkage.  
 
 
Figure 2.10 COSY and key KMBC correlations (left) and MS/MS fragmentations of 8 
and its ring-opened methanolysis product, respectively. 
HMBC analysis also revealed that the amide carbonyl at δC166.5 assigned to 
the methylsulfinylacetyl subunit was correlated to the Hα of Val-1 residue, 
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thus establishing the acetylation of the N-terminus in 8. Methanolysis of 8, 
followed by ESI (positive ion mode) MS/MS analysis of the obtained acyclic 
methyl ester derivative provided key fragment peaks, shown in Figure 2.10, 
giving definitive confirmation of the sulfinyltheonellapeptolide gross 
structure. In addition to the pseudomolecular ion at m/z 1454 [M + H]+, 
corresponding to the introduction of 32 mass units (MeOH) in the molecule, 
the ESIMS/MS spectrum provided several fragment ion peaks corresponding 
to N-terminus fragments due to the cleavage of the amide bond, and referred 
to as the b series in Roepstorff and Fohlman nomenclature42. In particular, 
the presence of the b2 fragmentation peak at m/z 331 supported, once again, 
the presence of the MeS(O)Ac unit. 
Complete acid hydrolysis of 8 and Marfey’s analysis37 on the hydrolysate 
(derivatization with L-FDAA, 1-fluoro-2,4-dinitrophenyl-5-L-alanine amide, 
followed by LC–MS comparison with the FDAA derivatives of appropriate 
standards) enabled us to determine the configuration of the chiral amino acid 
residues as L-MeAla, D-Leu (×2), D-MeLeu, L-Thr, L-Me-Val, L-Me- Ile, D-Me-
allo-Ile, D-Val and L-Val. This result left the ambiguity on the localization of 
the two methylisoleucine residues and of the two enantiomeric valine 
residues. Since the 1H and13C NMR resonances for the amino acids at 
positions 5–10 and 36–41 of 8 were almost superimposable with the 
corresponding values reported for theonellapeptolide Id (7)43, we assumed 
that the two peptides share the configurations at those positions, thus 
inferring the configurations of the two isoleucine residues. Similarly, it 
appeared reasonable to assume that, as in the co-occurring 
theonellapeptolide Id (and in all the theonellapeptolide found to date), the L-
Val could be the N-terminal amino acid and thus, the D-Val should be the 
amino acid at positions 28–32. A D-Val residue at these positions has been 
found previously in the structure of theonellapeptolide Ia44. The 
configuration at the stereogenic sulfur atom of 8 has been left undetermined. 
 
 
 
Chapter 2- Bioactive macrolides, depsipeptides and sterols from the sponge Theonella swinhoei 
45 
 
Table 2.3 1H (500 MHz) and 13C (125 MHz) NMR data of sulfinyltheonellapeptolide 
in CD3OD (8).  
AA Pos. δH, m, J in Hz δC AA Pos. δH, m, J in Hz δC 
L-Thr 1 - 171.2 β-Ala 33 - 173.2 
 2 4.36, m 58.5  34/34’ 2.29, m; 2.59, m 36.5 
 3 5.19, m 70.6  35/35’ 3.10, m; 4.23, m 36.8 
 4 1.11, d, 6.5 19.1 L-Me-
Ile 
36 - 172.5 
D-Me-
Ile 
5 - 173.4  37 3.14, m 71.2 
 6 5.06, m 62.5  38 2.48, m 36.5 
 7 2.14a 34.2  39/39’ 1.04, m; 1.92a 30.2 
 8 0.78, d, 7.2 11.5  40 1.00a 13.2 
 9/9’ 1.10, m; 1.38, m 26.5  41 0.81, d, 6.4 15.3 
 10 0.98, t, 7.6 17.0  37-NMe 3.35, s 39.9 
 6-NMe 3.22, s 32.0 D-Leu 42 - 176.2 
D-Leu 11 - 177.0  43 5.06, m 50.6 
 12 5.03, m 50.5  44 1.72a; 1.25a 41.2 
 13/13’ 1.74a, 1.25a 40.4  45 1.80a 26.6 
 14 1.81a 26.3  46 1.03a 21.0 
 15 0.89a 11.1  47 1.04a 25.0 
 16 0.94 d, 7.3 17.2 β- Ala 48 - 175.0 
β-Ala 17 - 174.3  49/49’ 2.28, m; 2.36, m 39.1 
 18/18’ 2.23, m 2.29 m 39.5  50/50’ 3.14, m; 3.81, m 37.7 
 19/19’ 3.24, m 3.69, m 38.2 D-Me-
Leu 
51 - 175.2 
L-Me-
Ala 
20 - 172.5  52 5.24, m 57.5 
 21 5.17a 58.5  53/53’ 1.41a; 2.03 m 39.5 
 22 1.45, d, 7.1 16.0  54 1.52a 27.1 
 21-NMe 2.77 s 30.5  55 0.83, d, 6.7 22.1 
L-Me-
Val 
23 - 173.0  56 0.95a 24.3 
 24 5.02a 59.4  52-NMe 3.30 s 33.0 
 25 2.40, m 30.2 L-Val 57 - 176.0 
 26 0.86a 20.6  58 4.76, m 57.7 
 27 0.92, d, 6.1 20.8  59 2.12, m 32.5 
 24-NMe 3.31 s 31.9  60 0.96a 20.4 
D-Val 28 - 173.2  61 1.01a 19.2 
 29 4.76, m 68.9 Me-
SAc 
62  166.5 
 30 2.68, m 27.6  63/63’ 3.67, d, 11.2; 58.9 
 31 0.86a 18.1   3.86, d, 11.2  
 32 1.17, d, 6.5 23.3  63-
SOMe 
2.79, s 39.2 
aOverlapped with other signals. 
Theonellapeptolide If (9, [α]D −26.7, c 1.0, MeOH) was isolated as a colorless 
amorphous solid and its molecular formula was established to be 
C68H121N13O16 by means of high resolution ESIMS. Inspection of 1H and 13C 
NMR spectra of 9 (CD3OD, Table 2.4) revealed extensive similarities with 
parallel data detected for 8. The most important differences could be 
recognized in the downfield shift of one methyl singlet (from δH 2.79, δC 39.2 
in 8 to δH 3.38, δC 59.1 in 9) and of a pair of mutually coupled doublets (from 
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δH 3.67 and 3.86, δC 58.9 in 8 to δH 3.88 and 3.97, δC 71.8 in 9). These data 
were easily rationalized with the replacement of the terminal 
methylsulfinylacetyl group with a methoxyacetyl group, a typical N-terminus 
acylating unit, already found in the theonellapeptolide family.  
Careful inspection of COSY and TOCSY spectra revealed also that, in 
agreement with the molecular formula, one isoleucine residue of 8 is 
replaced by a valine residue in 9. A subsequent combined analysis of 
homonuclear and heteronuclear 2D NMR spectra disclosed the presence of 
the following residues: three β-Ala, three Leu (one N-methylated), one N-
methyl-Ile, four Val (two N-methylated), one Thr, and one N-methylAla. As 
detailed for 8, the amino acid sequence of 9 was deduced by careful analysis 
of HMBC correlations and supported by the MS/MS spectrum of the 
methanolysis product mixture. Thus, theonellapeptolide If (9) has been 
identified as a new member of the theonellapeptolide family differing from 
theonellapeptolide Id (7) by the replacement of two isoleucine residues 
(positions 5–10 and 28–32) with valine residues. Complete acid hydrolysis of 
9 and Marfey’s analysis on the hydrolysate mixture provided the 
configuration of the chiral amino acid residues as L-MeAla, D-Leu (×2), D-
MeLeu, L-Thr, L-Me-Ile, D-Me-Val, D-Val, L-Me-Val and L-Val. With these data 
in hands, it was not possible to unambiguously define the exact localization of 
the valine residues. However, if we assume that the L-Val and L-Me-Val 
residues are localized at the same positions as in theonellapeptolide Id, then 
the positions of their enantiomeric counterparts are consequently deduced. 
In summary, compound 9 is a valine-rich theonellapeptolide, being the first 
member of this class to possess four valine residues.45 
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Table 2.4 1H (500 MHz) and 13C (125 MHz) NMR data of theonellapeptolide If (9) in CD3OD.  
AA Pos. δH, m, J in Hz δC AA Pos. δH, m, J in Hz δC 
L-Thr 1 - 169.2 β-Ala 33 - 173.2 
 2 4.38, m 57.5  34/34’ 2.29, m; 2.59, m 36.5 
 3 5.15, m 69.3  35/35’ 3.10, m; 4.17, m 36.8 
 4 1.13, d, 6.5 17.5 L-Me-
Ile 
36 - 172.5 
D-Me-
Val 
5 - 171.5  37 3.14, m 71.2 
 6 4.95, m 62.2  38 2.48, m 36.5 
 7 2.27a 26.7  39/39’ 1.04, m; 1.92a 30.2 
 8 0.76, d, 7.2 11.5  40 1.00a 13.2 
 9 0.99, d, 7.2 23.5  41 0.81, d, 6.4 15.3 
 6-NMe 3.17, s 31.3  37-NMe 3.35, s 39.9 
    D-Leu 42 - 176.2 
D-Leu 11 - 177.0  43 5.09, m 50.6 
 12 5.01, m 48.5  44 1.72a; 1.25a 41.2 
 13/13’ 1.65a, 1.25a 40.3  45 1.78a 26.6 
 14 1.74a 24.9  46 1.03a 21.0 
 15 0.96a 11.1  47 1.04a 25.0 
 16 0.98 d, 7.3 17.2 β- Ala 48 - 175.0 
β-Ala 17 - 174.3  49/49’ 2.28, m; 2.36, m 39.1 
 18/18’ 2.23, m 2.31 m 39.5  50/50’ 3.14, m; 3.81, m 37.7 
 19/19’ 3.15, m 3.85, m 38.2 D-Me-
Leu 
51 - 175.2 
L-Me-
Ala 
20 - 172.5  52 5.18, m 56.4 
 21 5.17a 58.5  53/53’ 1.41a; 2.03 m 39.5 
 22 1.45, d, 7.1 16.0  54 1.52a 27.1 
 21-NMe 2.77 s 30.5  55 0.83, d, 6.7 22.1 
L-Me-
Val 
23 - 173.0  56 0.95a 24.3 
 24 5.02a 59.4  52-NMe 3.30 s 33.0 
 25 2.40, m 30.2 L-Val 57 - 176.0 
 26 0.86a 20.6  58 4.98, m 54.6 
 27 0.92, d, 6.1 20.8  59 2.08, m 31.6 
 24-NMe 3.31 s 31.9  60 0.98a 20.4 
D-Val 28 - 173.2  61 1.01a 19.2 
 29 4.76, m 68.9 MeO-
Ac 
62  169.2 
 30 2.68, m 27.6  63/63’ 3.88, d, 11.2;  71.8 
 31 0.86a 18.1   3.97, d, 11.2  
 32 1.17, d, 6.5 23.3  63-OMe 3.38 59.1 
 aOverlapped with other signals.  
2.6 ANTIPROLIFERATIVE ACTIVITY OF SWINHOLIDES AND 
THEONELLAPEPTOLIDES. 
Swinholide A and many of its analogues have been demonstrated to be potent 
cell growth inhibitors active against several cancer cell lines, including KB 
cells (epidermal carcinoma), PC (lung carcinoma), L1210 (mouse leukemia), 
colon (SW480) and gastric aenocarcinoma (KATO-III). 7-24 It has been shown 
that swinholides exert their cytotoxic effect by disrupting the actin 
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cytoskeleton, a ubiquitous protein system essential for cell motility and 
cytokinesis in all eukariotes.46 The actin-swinholide complex has been 
investigated in detail by X-ray diffraction and observed that the macrolide 
binds simultaneously to two molecules of G-actin (globular form), forming a 
tertiary complex with the two side chains of the macrolide (from C-21 to the 
pyran ring) inhibiting polymerization by sequestration of G-actin, thus 
affecting many crucial cellular processes (Figure 2.11). Interestingly, the 
different size of the macrocyclic dilactone ring shown by isoswinholide A was 
responsible of a marked decrease of activity against L210 and KB cell lines 
(IC50 > 1 μM)36. On the other hand, bistheonellides, lacking one of the 
conjugated double bonds (C-2/C-3 and C-2’/C-3’), have been shown to link 
efficiently with actin but they are not able to cause breakage of actin 
strands.47 
 
Figure 2.11 Crystal structure of actin in complex with swinholide A. 
Theonellapeptolides are structurally similar to the widely used 
immunosuppressant drug cyclosporin A, sharing at least three important 
features: i) the exclusive presence of hydrophobic aliphatic amino acids; ii) 
the abundance of N-methylated residues and iii) the presence of a macrocycle 
made up by more than ten amino acids. Only a few theonellapeptolides have 
been tested for immunosuppressive activity and they revealed a moderate 
potency.26 In general, the potential bioactivity of this class of unique 
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cyclopeptides has not been investigated in great detail, and an inhibition of 
the development of fertilized eggs of sea urchin, an activity on the transport 
of Na+ and K+ ions 45, and a moderate cytotoxicity  have been reported. 
Considering all these data, swinholides and theonellapeptolides isolated 
during the present investigation (1-9) have been evaluated for their anti-
proliferative activity in HepG2 cells, an hepatic carcinoma cell line.  
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Figure 2.12 Anti-proliferative activity of theonellapeptolides 7-9 on hepatic 
carcinoma cell line.* 
*MTT assay was performed on HepG2 cells treated with increasing doses for 48 hours. Left 
panel: proliferation rate expressed as Δ% of absorbance compared to untreated cells. The 
values are expressed as mean ± SE. Right panel: computation of IC50 values. (A) 
Theonellapeptolide Id; (B) Sulfinyltheonellapeptolide; (C) Theonellapeptolide If (*<0.05 
compared to not treated cells; N=4). 
As reported in Figure 2.12, all tested theonellapeptolides showed 
antiproliferative activity at low micromolar doses, with a similar pattern of 
potency. At the dose 10 μM, the proliferation rate of HepG2 cells was 
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significantly reduced by theonallapeptolide Id (7), sulfinyltheonellapeptolide 
(8) and theonellapeptolide If (9) to about 50%, 30% and 50%, respectively 
(Figure 2.12, panels A, B and C; * p<0.05 compared to untreated cells; n = 4). 
Only theonellapeptolide Id was able to significantly reduce the proliferation 
at 1 μM. At this dose, the proliferation reduction was equal to 20% (Figure 
2.12, panel A; * p < 0.05 compared to untreated cells; n = 4). Computation of 
50% inhibitory drug concentration (IC50) revealed that compounds 7, 8 and 
9 were characterized by very similar IC50 values of about 1.5 μM for 
theonellapeptolide Id and 3 μM for sulfinyltheonellapeptolide and 
theonellapeptolide If. 
Table 2.5 IC50 and efficiency (as %  of growth inhibition 
relative to Swinholide A 100nM) of swinholides (1-6) on HepG2 
Compound IC50 (nM) Efficiency 
Swinholide A (1) 
 
20 - 
Swinholide B (2) 25 89.38 ± 4.1 % 
Swinholide D (3) 30 45.35 ± 1.4 % 
Isoswinholide A (4) 35  16.28 ± 1.7 % 
Isoswinholide B (5) 1500 7.52 ± 1.2 % 
Swinholide K (6) 15 42.67 ± 0.85 % 
On the other hand, all tested swinholides showed anti-proliferative activity at 
nanomolar doses, with the exception of isoswinholide B: with this compound 
a block of proliferation was observed at 1μM (Fig. 2.13 E; *p<0.05 vs NT, 
n=4). Swinholides A (1) B (2) showed very similar anti-proliferative 
capability: at the dose 100 nM both compounds reduced proliferation rate of 
HepG2 cells approximately of 50% (Fig. 2.13 A-B; *p<0.05 vs NT, n=4). 
Moreover, swinholide A was able to significantly reduce proliferation at 10 
nM (Fig. 2.13 A; *p<0.05 vs NT, n=4). Swinholide D and isoswinholide A were 
less potent compared to swinholide A, with an efficiency of 45% and 7%, 
respectively (Fig. 2.13 C-D; *p<0.05 vs NT,n=4. Table 2.5). Finally, 
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swinholide K (6) reduced significantly growth rate in HepG2 cells both at 10 
nM and 100 nM, showing an IC50 value of about 15 nM, but its efficiency was 
about 42% compared to swinholide A (Fig. 7F; *p<0.05 vs NT,n=4. Table 
2.5).These data support the observation that the size of the dilactone ring has 
a crucial impact on the activity and this effect would be worthy of a more 
detailed investigation. Interestingly, the new swinholide K exhibited a similar 
(slightly lower) IC50 value but a halved efficiency compared to that of 
swinholide A. 
 
Figure 2.13 Anti-proliferative activity of swinholides (1-6) on hepatic carcinoma 
cell line.* 
*MTT assay was performed on HepG2 cells treated with increasing doses of swinholides for 
48 hours. Left panel: proliferation rate expressed as Δ% of absorbance compared to 
untreated cells. The values are expressed as mean ± SE. Right panel: computation of IC50 
values. (A) Swinholide A; (B) Swinholide B; (C) Swinholide D; (D) Isoswinholide A; (E) 
Isoswinholide B; (F) Swinholide K. (*<0.05 compared to untreated cells; N=4). 
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2.7. 4-METHYLENESTEROLS: TYPICAL THEONELLA 
METABOLITES 
The investigation of Theonella swinhoei steroidal fraction has resulted in the 
isolation of several members of the 4-methylenesteroids family.  The rare 4-
methylenesteroids represent the exclusive elements of the steroid biogenetic 
class in Theonella sponges with conicasterol (10) and theonellasterol (11) as 
ideal biomarkers of Theonella conica and Theonella swinhoei, respectively48. 
 
 
 
These molecules share substituents and unsaturations on tetracyclic core but 
differ in the side chain with a 24S-ethyl group in theonellasterol and a 24R-
methyl group in conicasterol. 4-methylenesteroids are endowed with 
peculiar pharmacological profiles, ranging from selective antagonism on 
FXR49 to dual modulation on FXR/PXR; Theonella sponges genus is an 
invaluable source of NRs ligands.50 
In particular, during my PhD period, two known theonellasterols (E and F) 
(12-13), two known conicasterols (D and E) (14-15) and one new side chain 
modified sterol, 24-dehydroconicasterol D (16), with an additional 
methylene group in position 24, have been isolated. 
This new metabolite has been evaluated by the group of Prof. Fiorucci 
(University of Perugia-Italy) for interaction with the nuclear receptor FXR, 
together with which some natural and semisynthetic analogues (obtained in 
the laboratories of Prof. D’Auria, University of Naples), while compounds 12-
13-14-15 were already tested for this activity51-52. 
Structural elucidation of compounds 16 was helped by comparison of 
spectroscopic data with those of known analogue, indeed it showed NMR 
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signals of the tetracyclic core superimposable to the one of already published 
derivative conicasterol D (14).53 
 
 
COSY analysis of the 1H NMR spectrum of 24-dehydroconicasterol D (16) (see 
Experimental Section, paragraph 2.9.2), C29H46O3 by HR-ESIMS, indicated 
that its side chain should include an sp2 methylene, three methyl groups (all 
doublets at δH 0.99, 1.09 and 1.10), two sp3 methines and two sp3 methylenes. 
The HMBC correlations of the sp2 methylene with C-23, C-24 and C-25 
indicated its attachment at C-24, thus defining the structure of compound 4 
as a new sterol differing from conicasterol D (14) for the presence of an 
additional double bond between C-24 and C-28.  
2.8 PXR MODULATION ACTIVITY OF THEONELLA STEROIDS 
24-Dehydroconicasterol D (16) together with which some natural and 
semisynthetic conicasterol analogues were evaluated on PXR in a luciferase 
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reporter assay on a human hepatocyte cell line (HepG2 cells), in collaboration  
with Prof. Fiorucci (University of Perugia). 
Nuclear receptors (NRs) are a large superfamily of ligand-dependent 
transcription factors that regulate expression of genes involved in 
metabolism, homeostasis, growth and differentiation, aging, and 
reproduction.54 These regulatory proteins have a common evolutionary 
history as evidenced by their similar sequences and overlapping cellular 
functions. In addition, their ligands are often not selective for one particular 
NR, but rather are partial or full agonists for several receptors.  
Despite a complex organization, the NR family has a long history of successful 
drug discovery and those that have been deorphanized thus far have proved 
to be druggable; in other words, their activity can be modulated by small 
molecules.55 Drugs exploiting NRs represent 10–15% of the global 
pharmaceutical market are a mainstay of treatment in various human 
conditions including diabetes, hyperlipidemias, contraception, hormone 
replacement therapy, osteoporosis and cancers.56 
Pregnane-X-receptor (PXR) is a member of nuclear receptors (NRs) super-
family. PXR plays a fundamental role in protecting body tissues from 
xenobiotics and toxic bile acids.57 PXR is almost exclusively expressed in the 
gastrointestinal tract and liver, with lower levels in the kidney and ovary. 
PXR dysfunction is associated with immune disorders including PBC 
(primary biliary cirrhosis), PSC (primary sclerosing cholangitis) and 
inflammatory bowel diseases (IBDs), a family of highly prevalent disorders 
encompassing two major diseases: ulcerative colitis and Crohn’s disease. 
Apart crucial role in regulating drug detoxification, PXR plays also pleiotropic 
role of endobiotic metabolism. PXR regulates bile acids homeostasis,58,59 
glucose and lipid metabolism,60,61 energy homeostasis, immune responses62 
and, notably, drug-drug interactions. As a result, PXR ligands (agonists and 
antagonists) are recognized opportunity for the pharmacotherapy of several 
human diseases including diabetes and obesity, dyslipidemia, liver disorders, 
immune mediate dysfunctions and cancer. 
Expectedly, in the last decades a considerable number of chemicals have been 
show to function as PXR ligands, including several natural compounds 
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isolated from herbal medicines and marine organisms, which have 
highlighted the potential of novel chemical scaffolds useful for the 
development of PXR ligands.  
In this context several compounds isolated from marine sponges have been 
described to be endowed with agonistic activity on PXR, including 
solomonsterols, side chain truncated steroids,63 and the large family of 4-
methylenesteroids from Theonella swinhoei.64-65  
24-dehydroconicasterol D (16), together with other three new side chain 
modified 4-methylenesteroids named preconicalsterol (17) and 24-
dehydrotheonellasterol (18) and with some semisynthetic compounds (19-
20-21-22-23), isolated or obtained from conicasterol (10), allowed to 
speculate on the effect of punctual modifications on ring A and on the side 
chain toward PXR modulation and, notably, to identify a new chemotype of 
PXR antagonist. 
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These molecules were evaluated on PXR in a luciferase reporter assay on 
human hepatocyte (HepG2 cells) transiently transfected with pSG5-PXR, 
pSG5-RXR, pCMV-βgalactosidase, and p(CYP3A4)-TK-Luc vectors (Figure 
2.14). HepG2 cells were stimulated with compounds 16-23 in the presence 
or in absence of rifaximin, a well characterized PXR agonist (10 µM). As 
shown in Figure 2.14, compounds 17 and 21, when administered alone, 
partially transactivate PXR whereas 19 at 50 µM dose was relatively effective 
in inhibiting PXR transactivation caused by rifaximin, thus behaving as an 
antagonist. Even if partial inhibitions of PXR transactivation caused by 
rifaximin are shown in Figure 18B, none compound of this series could be 
judged an effective antagonist. In details, when cells were co-exposed to 
compounds 17 and 21 and rifaximin, the two compounds caused a slightly 
reversion of the pharmacological effect of rifaximin. This finding is common 
when a full agonist (rifaximin) is mixed with partial (less potent) agonists 
such as compounds 17 and 21. As concern compound 19, even if a slight 
antagonistic effect was demonstrated at 50 mM, this behavior was not 
confirmed when 19 was co-administered with rifaximin at different 
concentration.66 
 
 
Figure 2.14 Transactivation assay performed on HepG2 cells transiently transfected 
with full-length FXR,RXR, βgal and the canonical FXRE containing 3 inverted repeats 
(IR1). * 
*At 24 h post-transfection, cells were primed with (A) Rifaximin (R) and compounds 16-23 
10μM or with (B) compounds 16-23 50 μM plus Rifaximin 10 μM for 18 h (*: p< 0.05 versus 
not treated cells; #: p< 0.05 versus Rifaximin). 
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To further investigate the structure-activity, a substitution of the 
exomethylene at C-4 with a methyl appendage to produce derivatives 19, 20, 
21, and 23 has been perfomed, with only 21 still able to fit in PXR-LBD. 
Compatible with the large contribution of apolar aminoacids in PXR LBD, the 
introduction of an additional polar group on ring A in derivative 22 causes a 
loss of activity in luciferase reporter assay. Second, in the derivatives that still 
retain the exomethylene functionality, the substitution on the side chain 
produces a high impact on PXR activity. Similarly to theonellasterol, a potent 
and selective FXR antagonist devoid of any activity toward PXR and other 
metabolic NRs,49 compound 18, with an ethyl group at C-24, was inactive. 
Also in vitro data on 16 and 17 are quite interesting. 24-dehydroconicasterol 
D (16) shares the tetracyclic core with the PXR agonists theonellasterol E 
(12) and conicasterol D (14) and the side chain with the inactive 
dehydroconicasterol.65 The observed loss of activity for 16 points the 
attention on the negative effect played by the presence of an exomethylene 
functionality on the side chain of this reach family of marine PXR ligands. On 
the other hand preconicasterol (17), endowed with a cholestan-type side 
chain, maintains an agonistic behavior toward PXR. Then the concentration-
response curve for preconicasterol (17) and semi-synthetic derivative 21 
was investigated. As shown in Figure 2.15, compounds 17 and 21 
transactivate PXR with an EC50 of 21 mM and of 18 mM, thus indicating a 
dose dependent agonism towards PXR for both conicasterol derivatives. 
To further characterize these derivatives, the effect of compounds 17 and 21 
on the expression of CyP3A4 (cytochrome P) and on Multidrug Resistance 
Proteins (MDR1 and MPR3), three canonical PXR target genes, was examined 
by RT-PCR. As shown in Figure 2.16, the exposure of HepG2 cells to 17 and 
21 increased the expression of mRNA for the above PXR targeted genes, 
thereby confirming at molecular level that this compound is a PXR agonists. 
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Figure 2.15 Concentration response-curves for 17 and 21.* 
*HepG2 cells were transfected for PXR transactivation assay and stimulated with rising 
concentrations of 17 and 21 (1, 10 and 50 µM). Rifaximin (1, 10 and 50 µM) was used as a 
positive control to evaluate the PXR transactivation. RLU: Luciferase Relative light Units, 
RRU: Renilla Relative light Units. Results are expressed as mean ± standard error; *p < 0.05 
vs not treated cells. 
To elucidate at the atomic level the interaction between PXR and the 4-
methylenesteroids derivatives, docking calculations on the most active 
compounds of the series have been performed. In particular, three different 
x-ray structures of the PXR LBD (pdb codes: 3hvl, 1nrl and 1m13) have been 
used to take into account the conformational plasticity of the binding site. In 
fact, docking software treats protein as a rigid body, thus the use of multiple 
conformations of the target, if available, is advisable to increase the chances 
of success of the calculation. In the present case, the agonist compounds, 
preconicasterol 17 and derivative 21 were undergone to the docking 
calculations that predict a very similar binding behavior for both agonists in 
PXR-LBD. In particular, considering the docking results obtained using the 
three LBD x-ray structures, the most occurring binding mode of 
preconicasterol 17 and derivative 21 is that shown in Figure 2.17. 
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Figure 2.16 Real-Time PCR analysis of mRNA relative expression of the PXR target 
genes CYP3A4, MDR1, MPR3 in HepG2 cells treated with Rifaximin (10 µM), 17 and 
21  (10 µM).*  
*Values are normalized relatively to GAPDH mRNA and are expressed relative to those of not 
treated cells (NT), which are arbitrarily set to 1. (*:p< 0.05 vs not treated cells). 
In this state, the hydroxyl group on the ring A of preconicasterol 17 and 
derivative 21 engages H-bond interactions with the backbone carbonyl 
oxygens of His407 and Thr408. These interactions represent the anchor 
point of the ligands in the LBD with the rest of the molecule oriented in the 
binding pocket forming further favorable interactions such as hydrophobic 
contacts between the Me-19 and the ring A with residues such as Met243, 
Phe251, Met425 and Phe429. In particular, the last two residues are located 
in the activation function 2 region (AF-2) on a small flexible alpha helix (AF-2 
helix) responsible for the binding of the co-activator and co-repressor 
peptides. This part of the protein is supposed to undergo conformational 
motion responsible for the transition of the nuclear receptor from the agonist 
to the antagonist form. A similar mechanism of action has been very recently 
suggested by us and other authors for other nuclear receptors.67-68-69 On this 
background, it is reasonable to think that the hydrophobic package 
established at the AF-2 region by agonist compounds such as preconicasterol 
17 and derivative 21, stabilizes PXR in the agonist conformation. 
Finally, in the LBD, the steroidal scaffolds of 17 and 21 engage similar 
interactions with residues such as Leu209, while the flexible aliphatic tails 
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are settled in a very hydrophobic pocket. Here, preconicasterol 17 and 
derivative 21 establish a number of favorable contacts with residues such as 
Phe288, Trp299, Tyr306 and Met246 (Figure 2.17A and 2.17B). 
 
 
 
Figure 2.17 Representation of the binding mode of the agonist preconicasterol 17 
(violet sticks in A) and 21 (cyan sticks in B) predicted by docking calculations in the 
PXR LBD (PBD code 3HVL).* 
*PXR is shown as green cartoon, while AF-2 helix is colored in orange. Amino acids involved 
in ligand binding are shown as green and orange sticks. Residues from Pro268 to Arg287, 
from Ser350 to Arg360, and all hydrogens are omitted for clarity. 
Of relevance despite the different stereochemistry at C-3 on ring A and the 
presence of a methylene group in preconicasterol 17 instead of the methyl 
one in derivative 21, the binding pattern of these compounds is very similar, 
supporting the reproducibility and the reliability of the docking calculations. 
In conclusion, NRs play a key role in cellular homeostasis, controlling a wide 
range of reactions through the regulation of the transcription of specific 
target genes. This receptor family shares common structural features such as 
the presence of the LBD responsible for the binding of ligands and co-
activator peptides necessary to activate the gene transcription. Despite these 
similarities, each nuclear receptor shows a specific pattern of interaction 
with its ligands that, together with the conformational plasticity of the LBD, 
hampers the rational drug design of new active molecules. In this scenario, 
elucidating the molecular requisites for the binding to a specific nuclear 
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receptor represents an important advance to understand its functional 
mechanisms and provide the bases for an exogenous control of its activity.  
In this framework, we have developed a series of 4-methylenesteroids 
derivatives, originally isolated from Theonella marine sponges, as novel 
modulators of the nuclear receptor PXR. We have assessed their activity 
profiles through a number of pharmacological experiments and, with the aid 
of computational studies, we have investigated the effects of different 
modificatins on ring A and on the side chain of the 4-methylenesteroids 
derivatives toward PXR. Our results led to the identification of the first 
example of PXR antagonist with a steroidal scaffold, also elucidating the 
molecular requisites for PXR interaction. This study reaffirms the role of 
natural products as essential chemical probes in the today’s research arsenal 
to shed light on complex biological processes and biochemical pathways. 
2.9 EXPERIMENTAL SECTION  
2.9.1 Animal material, Extraction and Isolation 
Theonella swinhoei (order Lithistida, family Theonellidae) was collected in 
the Bunaken Marine Park of Manado (North Sualwesi, Indonesia) in January 
2010 and frozen immediately after collection. A reference sample of the 
sponge has been saved at the Department of Pharmacy, University of Naples 
Federico II, with the code Man-10-06. The frozen material (16.5 g) was 
extracted with methanol (3 × 1.5 L) at room temperature and the crude 
methanolic extract was subjected to a modified Kupchan’s partitioning 
procedure as follows. The methanol extract was dissolved in a mixture of 
MeOH/H2O containing 10% H2O and partitioned against n-hexane (1.81 g). 
The water content (% v/v) of the MeOH extract was adjusted to 30% and 
partitioned against CHCl3 (4.76 g). The aqueous phase was concentrated to 
remove MeOH and then extracted with n-BuOH (2.0 g). The CHCl3 extract was 
chromatographed by silica gel MPLC using a solvent gradient system from 
CH2Cl2 to CH2Cl2:MeOH 8:2. Fractions eluted with CH2Cl2:MeOH 97:3 (3 mg) 
were further purified by HPLC on a Luna 5µ100-5 C18 (5µm; 4.5 mm i.d. x 
250 mm) with MeOH:H2O (95:5) as eluent (flow rate 0.8 mL/min) to give 0.2 
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mg of 24-dehydroconicasterol D (16) (tR=9 min).Fractions eluted with 
CH2Cl2:MeOH 95:5 (174.5 mg) were further purified by HPLC on a Nucleodur 
100-5 C18 (Phenomenex) (5 μm; 7.8 mm i.d. × 250 mm) with MeOH:H2O 
(85:15) as eluent (flow rate 0.9 mL/min) to give swinholide A (1) (43.3 mg), 
swinholide B (2, 2.4 mg), swinholide D (3, 2.2 mg), isoswinholide A (4, 2.0 
mg), isoswinholide B (5, 2.7 mg), swinholide K (6, 5.3 mg). Fractions eluted 
with CH2Cl2:MeOH 9:1 (853.3 mg) were further purified by silica column 
followed by HPLC on a Nucleodur 100-5 C18 (Phenomenex) (5 μm; 7.8 mm i.d. 
× 250 mm) with MeOH:H2O (9:1) as eluent (flow rate 0.9 mL/min) to give 
theonellapeptolide Id (7) (68.5 mg), sulfinyltheonellapeptolide (8, 4.6 mg) 
and theonellapeptolide If (9, 2.1 mg).  
2.9.2 Spectroscopic data for the isolated compounds 
Isoswinholide B (5): white powder; [α]D25 - 7.4 (c 0.02, CH3OH); 1H and 13C 
NMR data in CD3OD given in Table 2.1; ESIMS: m/z 1411.9 [M+Na]+. HRMS 
(ESI): calcd for C78H132NaO20: 1411.9210; found 1411.9216 [M+Na]+. 
Swinholide K (6): white powder; [α]D25 - 15.2 (c 0.04, CH3OH); 1H and 13C 
NMR data in CD3OD given in Table 2.2; ESIMS: m/z 1427.9 [M+Na]+. HRMS 
(ESI): calcd for C78H132NaO21: 1427.9159; found 1427.9167 [M+Na]+. 
Sulfinyltheonellapeptolide (8): colorless amorphous solid; [α]D25 – 38.0 (c 
0.1, CH3OH); 1H and 13C NMR data in CD3OD given in Table 2.3; ESIMS: m/z 
1423 [M+H]+ and 1445 [M+Na]+. HRMS (ESI): calcd for C69H123N13NaO16S: 
1444.8829; found 1444.8834 [M+Na]+. 
Theonellapeptolide If (9): colorless amorphous solid; [α]D25 – 26.7 (c 0.1, 
CH3OH); 1H and 13C NMR data in CD3OD given in table 2.4; ESIMS: m/z 1377 
[M+H]+ and 1399 [M+Na]+. HRMS (ESI): calcd for C69H121N13NaO16: 1398.8952; 
found 1398.8949 [M+Na]+. 
24-dehydroconicasterol D (16): white amorphous solid; [α]D25-67.0 (c 0.02, 
CHCl3); 1H-NMR (C6D6): δ 5.35 (HA-29, 1H, br s), 4.93 (HA-28, 1H, br s), 4.90  
(HB-28, 1H, br s), 4.74 (HB-29, 1H, br s), 4.47 (H-15, 1H, br d), 3.88 (H-3, 1H, 
m), 2.70 (H-5, 1H, br d, J= 12.51 Hz), 2.54 (HA-7, 1H, m), 2.37 (HB-7, 1H, ddd, J= 
1.8, 4.7, 14.6), 2.27 (H-25, 1H, hep, J= 6.8), 2.24 (HA-23, 1H, m), 2.07 (HA-1, 1H, 
m), 2.01(HB-23, 1H, m), 1.90 (HA-2, 1H, m), 1.82 (HA-16, 1H, m), 1.81 (HA-11, 
1H, m), 1.76 (HA-12, 1H, m), 1.69 (HA-22, 1H, ovl), 1.62 (H-17, 1H, m), 1.59 (HA-
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6, 1H, m), 1.55 (HB-11, 1H, m), 1.54 (HB-16, 1H, m), 1.50 (H-20, 1H, ovl), 1.41 
(HB-12, 1H, m), 1.39 (HB-6, 1H, m), 1.37 (HB-2, 1H, m), 1.35 (HB-1, 1H, m), 1.34 
(HB-22, 1H, ovl), 1.10 (H- 27, 1H, J= 6.8), 1.09 (H- 26, 1H, J= 6.8), 0.99 (H- 21, 
1H, J= 6.7), 0.71 (H- 18, 1H, s), 0.68 (H-19, 1H, s) ppm; 13C-NMR (C6D6): δ 154.2 
(C-4), 150.3 (C-14), 135.3 (C-8), 105.8 (C-28), 103.7 (C-29), 74.9 (C-9), 73.0 (C-
3), 69.6 (C-15), 53.7 (C-17), 44.2 (C-13), 43.8 (C-10), 41.7 (C-5), 39.4 (C-16), 
39.2 (C-24), 34.9 (C-20), 34.4 (C-12), 33.8 (C-22), 33.4 (C-2), 32.7 (C-25), 30.6 
(C-23), 30.1 (C-1), 29.2 (C-11), 27.1 (C-7), 24.8 (C-6), 20.3 (C-27), 19.2 (C-21), 
18.4 (C-26), 18.3 (C-18), 17.0 (C-19) ppm. HRMS-ESI m/z 443.3527 [M+H+], 
C29H47O3 requires 443.3525. 
2.9.3. Evaluation of antiproliferative activity 
HepG2 cells were plated in a 24-wells plate at 3×104 cells/well, in Minimum 
Essential Medium with Earl's salts containing 10% fetal bovine serum (FBS), 
1% L-glutamine and 1% penicillin/streptomycin. On day 2, cells were treated 
with increasing doses of Swinholide A (1, 10 and 100 nM), Swinholide B (1, 10 
and 100 nM), Swinholide D (1, 10 and 100 nM), Isoswinholide A (1, 10 and 100 
nM), Isoswinholide B (0.001, 0.01, 0.1, 1 and 10 μM), Swinholide K (1, 10 and 
100 nM), Theonellapeptolide Id (0.1, 1 and 10 μM), Sulfinyltheonellapeptolide 
(0.1, 1 and 10 μM) and Theonellapeptolide If (0.1, 1 and 10 μM) for 48 hours. 
On day 4 MTT assay was assessed; 100 μL of MTT solution (5mg/ml) were 
added to each well and cells were incubated at 37°C for 4 hours. After 
incubation, colture medium was removed and 1mL of DMSO was added to each 
well; absorbance was read using spectrophotometer at 590 nM. Proliferation 
rate was reported as delta of absorbance compared to untreated cells; values 
are expressed as mean ± SE. For each compound, IC50 was evaluated as follow: 
inhibition of proliferation was expressed as percentage compared to the 
inhibition of proliferation observed at the highest dose of any experimental 
setting (which was arbitrarily assigned a value of 100%). 
2.9.4. Luciferase assay 
HepG2 cells were cultured at 37 °C in Minimum Essential Medium with Earl’s 
salts containing10% fetal bovine serum (FBS), 1% L-glutamine and 1% 
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penicillin/streptomycin. Cells were plated in a 24-wells plate at 5 × 104 
cells/well. The transfection experiments were performed using Fugene HD 
(Promega, Milan, Italy) according to manufacturer specifications.For PXR 
mediated transactivation, cells were transfected with 75 ng pSG5-hPXRT1, 75 
ng pSG5-RXR, 125 ngpCMV-βgal and with 250 ng of the reporter vector 
pGL3(henance)PXRE. At 24 hours post-transfection, cells were primed with 
rifaximin or compounds 16-23 1-0μM (agonism) or with compounds 16-23 
50μM plus rifaximin 10μM (antagonism) for 18 hours. 20 μL of cellular 
lysates were read using the Luciferase Substrate (Promega) and 
luminescence was measured using the Glomax 10/10 luminometer 
(Promega). Luciferase activities were normalized for transfection efficiencies 
by dividing the relative light units by β-galactosidase activity expressed from 
co-transfected pCMV-βgal. 
2.9.5 Real Time PCR 
HepG2 cells were stimulated 18 h with rifaximin (10 μM), compounds 19 and 
21 (10 μM) or with the combination of compounds 19 or 21 (50μM) plus 
rifaximin (10μM). Total RNA was extracted using the TRIzol reagent 
(Invitrogen), and reverse-transcribed using random hexamer primers and 
Super Script-II reverse transcriptase (Invitrogen). mRNA was quantified by 
Real-Time quantitative PCR on iCycler apparatus (Biorad) using specific 
primers:hGAPDH: gaaggtgaaggtcggagt and catgggtggaatcatattggaa; 
hCYP3A4: caagacccctttgtggaaaa  and  cgaggcgactttctttcatc. For quantitative 
RT-PCR, 10 ng of template was dissolved in a 20 μl solution containing 200 
nM of each primer and 10 μl of KAPA SYBR FAST Universal qPCR Kit (KAPA 
BIOSYSTEMS). All reactions were performed in triplicate, and the thermal 
cycling conditions were as follows: 3 min at 95 °C, followed by 40 cycles of 95 
°C for 15 s, 58 °C for 20 s and 72 °C for 30 s. The relative mRNA expression 
was calculated accordingly with the Ct method. All PCR primers were 
designed using the software PRIMER3 (http://frodo.wi.mit.edu/primer3/) 
using published sequence data obtained from the NCBI database. 
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2.9.6 Computational Details 
Molecular docking of 17 and 21 in the three-dimensional X-ray structures of 
the PXR LBD (PDB codes: 3hvl, 1nrl and 1m13) without the co-crystallized 
inhibitor and waters were carried out using the AutoDock software package 
(version 4.2). Ligands and receptor structures were converted to AutoDock 
format files using the ADT software, and the Gesteiger-Marsili partial charges 
were then assigned.A box around the binding pocket has defined the docking 
area and grids points of 48×40×38 with 0.375 Å spacing were calculated 
within the this area for all the ligand atom types using AutoGrid4. For each 
ligand, 100 separate docking calculations were performed. Each docking run 
consisted of 25 million energy evaluations using the Lamarckian genetic 
algorithm local search (GALS) method. Otherwise default docking parameters 
were applied. The docking conformations were clustered on the basis of the 
root-mean square deviation values (rmsd tolerance = 1.5 Å) between the 
cartesian coordinates of the ligand atoms and were ranked based on the 
AutoDock scoring function. 
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CHAPTER 3 -HALOINDOLES FROM IOTROCHOTA 
PURPUREA 
In the frame of Bluegenics European project (From gene to bioactive product: 
Exploiting marine genomics for an innovative and sustainable European blue 
biotechnology industry, 311848, 7th Framework programme), a bioguided 
analysis of a specimen of Iotrochota purpurea (order Poecilosclerida, family 
Myxillidae) (Figure 3.1) collected in Indonesian Sea, has been undertaken 
during a visit period in the Muséum National d'Histoire Naturelle, in the 
research group of Dr. Marie-Lise Bourguet-Kondracki (CNRS-Paris, France).  
 
 
Figure 3.1 Iotrochota purpurea 
Marine sponges belonging to the genus Iotrochota are a promising source of 
diverse chemical metabolites with a wide range of bioactivity. Previous 
studies on marine sponges of the genus Iotrochota resulted in the isolation of 
haloindole derivatives, e.g. methyl (E)-3-(6-bromoindol-3- yl)-prop-2-
enoate,1 matemone2 and 6-bromoindole-3-carbaldehyde;2 the aromatic 
halogenated tyrosine derivatives3, e.g.  itampolins A and B4, the pyrrole 
derivative purpurone,5 ecdysteroids,6 6-hydroxy-4-en-3-one steroids.7 The 
cytotoxic glycosphingolipid iotroridoside A,8 3-octadecyloxy-1,2-propanediol 
(batyl alcohol),9 and ceramides10 have been isolated from Iotrochota ridley. In 
addition, the sponge Iotrochota baculifera was reported to contain 
sphingolipids and the glycosphingolipid iotroridoside B.11-12  
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The bioassay-guided fractionation of the crude extract of I. purpurea resulted 
in the isolation of a series of bromoindole derivatives, which were subjected 
to pharmacological assays to evaluate antikinase activity. 
3.1 HALOGENATED METABOLITES FROM SPONGES 
Unlike terrestrial organisms, marine organisms often produce halogenated 
secondary metabolites: the frequent occurrence of this kind of metabolites is 
a unique feature of marine natural product chemistry. They are not uniformly 
distributed among the marine plant and invertebrate taxa, and are most 
commonly found in red algae and sponges. Even in this latter phylum they 
are present in a relatively small number of species, and are mainly associated 
with horny sponges, which are distributed in the three orders Dictyoceratida, 
Dendroceratida, and Verongida. In particular, Verongida are characterized by 
their ability to synthesize bromotyrosine derivatives, which seem to be 
peculiar to these sponges, and have been suggested as chemical markers for 
taxonomic studies.13 Sponges belonging to the genus Iotrochota are a rare 
example of sponge that elaborates such metabolites not belonging to the 
order Verongida.  
Many sponges are symbiotic organisms and the content of microbial 
endosymbionts in them can be very significant and comparable in the mass 
and volume to the cells of the host: this fact appears to explain, at least partly, 
the vast variety of secondary  halogenated metabolites in sponges.  
The most widely represented among the classes of halogenated metabolites 
are alkaloids. A number of these alkaloids display high biological activities, 
including antimicrobial and antitumor activities. Among the halogenated 
alkaloids, bromoalkaloids form the most widely distributed group, which are 
predominantly found in marine eukaryotes, are significantly rarer in 
prokaryotic microorganisms, and are almost absent from terrestrial plants 
and animals.14-15 Iodoalkaloids compose a rare group of natural compounds 
that has up until now only been isolated from marine organisms.14-15-16 
Chloro-containing alkaloids are widely distributed in nature and have been 
isolated until now from microorganisms, plants, terrestrial animals, and 
marine invertebrates.17 
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Thus, in sponge the following large groups of halogenated alkaloids are 
represented: indole alkaloids, including diverse tryptamine derivatives, bis- 
and trisindole compounds, pyrrole-containing alkaloids and, finally, the 
alkaloids derived from dibromotyrosine. Some other smaller series of 
compounds are the pyrroloquinoline, and different classes of peptides. 
Cytotoxicity towards tumor cells, antimicrobial activity, and antifungal action 
are typical of the halogenated alkaloids. Other types of biological activities 
are rarely found. 
3.1.1 Bromoindole alkaloids 
Structural analysis of many halogenated alkaloids from sponges indicates 
that they derive biogenetically from tryptophan, known to be one of the basic 
amino acids in eukaryotic organisms, and, hence, it was not surprising that 
halogenated indoles were found in numerous natural sources, including 
marine invertebrates.18-19 Bromoindole alkaloids were isolated from various 
marine sponge species, for example Oceanapia bartschi20, Pleroma menoui21, 
Plocamissma igzo22, and Pseudosyberites hyalinus.23 
The oxindole system is an analogue of the indole nucleus found in a large 
number of naturally occurring products. It is a benzopyrrolidinone, with the 
pyrrolidinone ring fused to the benzene ring, and the carbonyl group being 
either in the 2- or the 3-position of the nucleus. In particular, 3-indolinones 
have been found in terrestrial sources.24-25 Their derivatives have been 
identified as antibiotic compounds produced by bacteria isolated from the 
toxic mucus of the boxfish26 and by symbiotic bacteria of crustacean 
embryos.27 Dimers of 3-indolinone are responsible for the bright colors of 
mollusks, such as the Tyrian purple of Muricidae and Thaisidae.28 Indolinone 
derivatives and bromoindole metabolites are often proposed to be repellent 
or antifeedant substances. Bromoindoles have also been reported to show 
antimicrobial, antiproliferative, and antifouling effects.29 
Recently, matemone (1), a bromine-containing 3-oxindole alkaloid, has been 
isolated from Iotrochota purpurea, found off the coast of Mozambican 
Matemo Islands.7 Matemone is marginally active against the bacterium 
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Staphylococcus aureus and has significant binding affinity to DNA. It also 
showed activity against a panel of cancer cell lines.  
Other bromine-containing indole alkaloids from Iotrochota purpurea are 
iotrochamide B (2), an N-cinnamoyl-amino acid with activity towards 
Tripanosoma brucei brucei, and Purpuroine J (3). 
 
 
 
Many simple and complex haloindoles and 3-oxindoles have thus been 
designed, synthesized and screened for activity against diseases targeting 
specific enzymes. Indeed, the kind of halogenated heterocycles are currently 
explored for different targets and, among them, inhibition of cyclin 
dependent kinases (CDKs) appear one of the most promising. CDKs have a 
vital role of regulating cell cycle events in malaria30 and a variety of human 
cancer cells.31 The activity of CDKs depend on a regulatory subunit called 
cyclin which binds to and activates the relevant CDKs. Direct inhibitors are 
preferably low molecular weight compounds that block the enzymatic 
activity of the CDKs.32 
Therefore, the final goal of bioassay-guided fractionation of the crude extract 
of I. purpurea was the isolation of derivatives with anti-kinase activity. 
3.2 ISOLATION AND STRUCTURAL ELUCIDATION OF 
BROMOINDOLE DERIVATIVES 
Iotrochota purpurea  (order Poecilosclerida, family Myxillidae) was collected 
in South Sulawesi (Spermonde Archipelago off Ujung Pandang). The material 
was sequentially extracted with dichloromethane, ethyl acetate and butanol, 
to obtain CH2Cl2, AcOEt and BuOH extract. Each extract was subjected to flash 
chromatography with a gradient CH2Cl2/MeOH of increasing polarity to 
obtain six fractions from each extract. Preliminary pharmacological assays, 
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performend by Prof. Laurent Meijer in laboratory ManRos Therapeutics 
(Roscoff-France), showed antikinase activity for each extract and selected 
some specific fractions obtained from flash chromatography. 
These active fractions were further purified by semipreparative and analytic 
RP-HPLC. The analysis of CH2Cl2 and BuOH extracts afforded the isolation of 
three known bromoindole derivatives (4-5-6) and one new brominated 3-
oxindole derivatives (7). 
 
 
The dichloromethane extract of Iotrochota sponge yielded three known 
bromoindole derivatives (4-5-6), previously isolated from other sponges 
Pseudosuberitis hyalinus, Pleroma menoui and also from Iotrochota purpurea. 
These compounds were identified on the basis of the identity of their 
spectroscopic data with those published in the literature.20-22 The BuOH 
extract contained the new 3-oxindoles brominated derivative 7, which we 
named matemone B. 
Matemone B (7) was obtained as a yellow film. The molecular formula was 
determined as C12H9NO5BrNa by HRESIMS; the mass spectrum gave a double 
peak at 349/351 (1:1 ratio), suggesting the presence of one bromine atom in 
the molecule. The 1H NMR spectrum of 7 showed the presence of a 
trisubstituted aromatic ring (ortho, meta, meta) [δ 7.70 (1H, d, J =7.6 Hz), 
7.33 (1H, dd, J= 7.6, 1.6 Hz), 7.32 (1H, d, J = 7.6 Hz)], a methoxy group at δ 
3.49 (3H, s) and two aliphatic protons at δ 3.19 (2H, s). The 13C NMR 
spectrum of 7 showed signals for seven unprotonated carbons (δ 192.4, 
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170.9, 170.7, 142.8, 129.8, 116.8, 73.0),  three sp2 methine (δ 129.3, 125.6, 
118.8), one sp3 methylene (δ 39.3) and one methyl group (δ 51.7).  
The NMR data of matemone B (7) support the presence of a trisubstituted 
aromatic ring, a conjugated ketone, one ester, one carboxylic acid, a 
methylene group, and a methoxy group. 
The connectivities observed in the 1H-1H COSY and HSQC spectra supported 
the placement of the bromine atom C-6 of an indole-type skeleton. The oxo-
indole subunit was confirmed by the HMBC connectivity between H-4 (δ 
7.70) and the ketone C-3 (δ 192.4). This HMBC connectivity, together with 
the ortho- and meta- proton couplings for H-5, confirmed the location of 
bromine atom at C-6. HSQC and selcted HMBC connectivities (shown as 
arrows in Fig. 3.2) allowed the unambiguous assignments of all proton and 
carbon resonances of 7. C-2 was assigned as an unprotonated sp3 carbon 
resonating at δ 73.0, on the basis of the HMBC cross-peaks of H2-1' with both 
C-2 and C-3. 
Matemone B includes one stereogenic center (C-2). Since [α]D of 7 was 0° and 
its CD spectrum was flat, we assume that matemone B exists as a racemic 
mixture. 
 
Figure 3.2 Key HMBC correlation for matemone B (7). 
Matemone B is related to matemone A since these two metabolites share the 
6-bromo-3-oxo-indole nucleus. However, in the case of 7, a methoxy group is 
replaced by a ketide unit (-CH2COO-) raising interesting questions about its 
biogenetic origin. 
3.3 ANTIKINASE ACTIVITY 
The cyclin-dependent kinases (CDKs) are a group of serine/threonine kinases 
involved in the regulation of the cell cycle, neuronal functions, transcription 
and apoptosis.33 Since in many human cancers hyperactivity of CDKs has 
been identified as one of the mechanisms underlying the pathological 
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hyperproliferation,34 the inhibition of CDKs may offer a therapeutic option 
for cancer patients.35-36 Consequently, a number of small molecules with 
CDK-inhibitory properties have been developed during the past decade.37-38 
At least four CDK inhibitors are currently under clinical trial as anticancer 
drugs: flavopiridol, the indole dimer UCN-01, roscovitine (CYC202; seliciclib), 
and the aminothiazole BMS-387032.39 
Three compounds isolated from Iotrochota purpurea extract (4-5-6) have 
been evaluated for their antikinase activity while, unfortunately, matemone B 
was isolated in too small amounts to be tested. For measurement of protein 
kinase inhibitory activities, a panel of nine different kinases involved in cell 
proliferation, diabetes and neurodegenerative disorders (dual-specificity 
tyrosine-(Y)-phosphorylation-regulated kinase 1A (DYRK1A), CDC-like 
kinase 1 (CLK-1), casein kinase 1 (CK-1), cyclin-dependent kinase 5 (CDK5), 
glycogen synthase kinase-3 (GSK-3), cyclin-dependent kinase 1 (CDK1), 
cyclin-dependent kinase 2 (CDK2/A) and complex of cyclin-dependent kinase 
9 and cyclin T (CDK9/cyclin T) and malaria (PfGSK-3) was used. 
Only compound 4 revealed antikinase activity with IC50 of 2, 10 and 6 μm 
against CDK9/cyclin T, CLK1 and DYRK1A, respectively, while it was inactive 
on the other five tested kinases. Given the wide structural similarity within 
these analogues, we should presume that compound 6 is favored by its lower 
polarity. 
This result inspires the search for new potential candidates for development 
of new therapeutics for treatment of cancer, diabetes, Alzheimer’s disease 
and malaria.40 
3.4 EXPERIMENTAL SECTION  
3.4.1 Animal material, Extraction and Isolation 
Iotrochota purpurea (order Poecilosclerida, family Myxillidae) was collected 
in South Sulawesi (Spermonde Archipelago off Ujung Pandang). The frozen 
material (500 g) was sequentially  extracted with dichloromethane, ethyl 
acetate and butanol (1 L for each solvent), to obtain CH2Cl2 (3.0 g), AcOEt (0.4 
g) and BuOH (1.2 g) extract. CH2Cl2 extract was subjected to flash 
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chromatography  with a gradient CH2Cl2/MeOH to obtain six fractions. 
Fraction number 5 (514.0 mg) was further purified by preparative HPLC on a 
C-18 column (Knauer, 300 x 8 mm, prefilled with C-18 Eurosphere) with a 
gradient H2O/AcCN (from 5% to 80% of AcCN, 0.1% formic acid), flow rate 
10 ml/min, to give compounds 4 (9.1 mg), 5 (5.8 mg) and 6 (3.0 mg). 
BuOH extract was subjected to flash chromatography  with a gradient 
CH2Cl2/MeOH to obtain six fractions. Fraction number 5 (445.0 mg) was 
further purified first by preparative HPLC on a C-18 column (Knauer, 300 x 8 
mm, prefilled with C-18 Eurosphere) with a gradient H2O/AcCN (from 5% to 
60% of AcCN, 0.1% formic acid), flow rate 10 ml/min, and then by 
semipreparative HPLC on C6 column (Gemini C6 phenyl) with a gradient 
H2O/AcCN (from 15% to 60% of AcCN, 0.1% formic acid), flow rate 3 ml/min, 
to give matemone B (7) (1.1 mg). 
3.4.2 Spectroscopic data for isolated compounds 
Matemone B (7): yellow film; [α]D250 (c 0.088, CH3OH); 1H-NMR (DMSO): δ 
11.0 (NH-1, 1H, bs), 7.70 (H-4, 1H, d, J =7.6 Hz), 7.33 (H-5, 1H, dd, J= 7.6, 1.6 
Hz), 7.32 (H-7, 1H, d, J = 7.6 Hz), 3.49 (H-2’’, 3H, s), 3.19 H-1’, 2H, s) ppm; 13C-
NMR (DMSO): δ 192.4 (C-1),  170.9 (C-1’’), 170.7 (C-2’), 142.8 (C-8), 129.8 (C-
9), 129.3 (C-4), 125.6 (C-5), 118.8 (C-7), 116.8 (C-6), 73.0 (C-2), 51.7 (C-2’’), 
39.0 (C-1’) ppm. HRMS-ESI m/z 351.9569 [M+Na+], C29H47O3 requires 
351.9567. 
3.4.3 Protein kinases assays 41 
Evaluation of the protein kinase activity was performed in vitro as previously 
described.42 Briefly, homogenization buffer: 60 mM β-glycerophosphate, 15 
mM p-nitrophenylphosphate, 25 mM Mops (pH 7.2), 15 mM EGTA, 15 mM 
MgCl2, 1 mM dithiothreitol, 1 mM sodium vanadate, 1mM NaF, 1 mM 
phenylphosphate, 10 µg leupeptin mL-1, 10 µg aprotinin mL-1, 10 µg soyabean 
trypsin inhibitor mL-1, and 100 µg benzamidine. Buffer A: 10 mM MgCl2, 1mM 
EGTA, 1 mM dithiothreitol, 25 mM Tris-HCl pH 7.5, 50 µg heparin mL-1. Buffer 
C: homogenization buffer but 5 mM EGTA, no NaF and no protease inhibitors. 
Kinase activities were assayed in duplicates in buffer A or C at 30°C, at a final 
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ATP concentration of 15 µM. The order of mixing the reagents was: buffers, 
substrate, enzyme, and inhibitor. Isolated compounds were tested against a 
panel of eight kinases; namely, dual-specificity tyrosine-(Y)-phosphorylation 
regulated kinase 1A (DYRK1A), cyclin-dependent kinase 5  (CDK5), glycogen 
synthase kinase-3 (GSK-3), CDC-like kinase 1 (CLK-1), casein kinase 1 (CK1), 
cyclin-dependent kinase 1 (CDK1), cyclin-dependent kinase 2 (CDK2), and 
complex of cyclin-dependent kinase 9 and cyclin T (CDK9/cyclin T). 
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CHAPTER 4 -ANTIMALARIAL AND ANTI-
INFLAMMATORY SESQUITERPENE LACTONES FROM 
VERNONIA AMYGDALINA 
The genus Vernonia Del. (family Asteraceae, tribe Vernoniae) includes over 
1000 species growing mostly, but not exclusively, in tropical regions and in a 
wide range of habitats, going from deserts to frosty areas.1 One of the most 
common members of this genus is V. amygdalina, a shrub of savannah and 
forests of tropical Africa, known with the name bitter leaf.  
People in the tropics use different parts of Vernonia amygdalina for its 
medicinal value for example, leaves for fever and malaria (East Africa,2-3 
Northeast Nigeria,4  Ghana5) and for tick control in West Ethiopia;6  roots for 
sexual transmitted disease in Guruve district, Zimbabwe.7 In Tanzania, 
chimpanzees have been observed to ingest the leaves instinctively when 
suffering from parasitic infections.8 Beyond Vernonia’s medicinal value, it is 
widely grown for edible soup in Cameroon and Nigeria.9 In Cameroon, leaves 
are sometimes eaten unprocessed and raw mixed with palm oil and salt.10 V. 
amygdalina is traditionally used also in the management and prevention of 
malaria.  
 
 
Vernonia amygdalina 
Not surprisingly, the thorough chemical investigation on V. amygdalina 
leaves have resulted in the characterization of a number of secondary 
metabolites, spanning from sesquiterpene lactones11-12-13 to stigmastane-type 
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saponins (vernoniosides),14 flavonoids,15 and peptides (edotides).16 
Sesquiterpene lactones have been recognized as the responsible of the 
marked activity on the blood stages of the Plasmodium parasite showed by V. 
amygdalina extracts.17 On the other hand, the anti-inflammatory and 
anticancer activities of Vernonia extracts have not been unambiguously 
correlated with a specific component since stigmastane steroids,18 
sesquiterpene lactones,19 polyacetylenes,20 and terpene glycosides21 have all 
been indicated as likely responsible for these activities. A recent study has 
demonstrated that the growth inhibition on human breast cancer cell lines 
exhibited by V. amygdalina extracts involved the stimulation of cell-type 
specific G1/S phase cell cycle arrest through a p53-independent pathway, 
with apoptosis occurring through both extrinsic and intrinsic pathways.22  
In the frame of my Ph.D. research, the bioguided analysis of a specimen of V. 
amigdalina has been undertaken as part of a project directed to the 
phytochemical analysis and pharmacological evaluation of plants from Africa, 
in collaboration with University of Camerino (Italy) and University of 
Cordoba (Spain). The study aimed at: 
 characterizing plant extracts for stage specific effects on gametocytes 
and sporogonic stages of Plasmodium falciparum and identifying the 
responsible compounds of antimalarial activity through a bioassay-
guided fractionation approach; 
 isolation and structural elucidation of compounds with Michael 
related bioactivity, capable of shedding light on the molecular 
mechanisms underlying the anti-inflammatory and anticancer 
activities detected for the extract. 
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4.1 TRANSMISSION BLOCKING ACTIVITY  
4.1.1 The burden of malaria 
It has been estimated that 300-500 million cases of malaria occur annually 
with 1.75 to 2.5 million deaths. Malaria is a particularly important disease in 
sub-Saharan Africa, where about 90% of cases and deaths occur, but is also a 
serious public health problem in certain regions of Southeast Asia and South 
America.23 
Human malaria is caused by four species of Plasmodium, namely P. 
falciparum, P. vivax, P. ovale and P. malariae, which are transmitted by female 
Anopheles mosquitoes. P. falciparum is the parasite that causes most severe 
diseases and most fatal cases.  
The life cycle, immunological defence mechanisms, and clinical development 
of malaria in humans is complex. The sporozoites that develop in the salivary 
glands of the female mosquito are inoculated into the human when then the 
insect bites to acquire a blood meal. The protozoans in the sporozoite form 
invade selectively the parenchymal cells of the human liver. In this stage, the 
patient remains asymptomatic and, after an average incubation period of 5-7 
days (in the case of P. falciparum), protozoa reach the merozoite stage and 
are released from the liver. The merozoites invade the erythrocytes and start 
feeding on the haemoglobin. After proliferation, the rupture of the 
erythrocyte membrane and the consequent liberation of other merozoites, 
that invade other erythrocytes, cause the massive infection and the 
symptoms. A small portion of merozoites develops into the sexual stage of 
gametocytes, a form that is able to re-start the life cycle of the malaria 
parasite when a mosquito takes a blood meal from an infected person2 
(Figure 4.1).  
The clinical symptoms of malaria infections are exclusively attributable to 
parasites in the erythrocytic stage. The rupture of infected erythrocytes is 
associated with the release into the blood stream of cell debris responsible 
for the characteristic fever spike patterns. In the lethal cases, a specific 
protein produced by the protozoan is embedded into the cell membrane of 
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the infected erythrocyte and, as a consequence of this modification, the 
erythrocyte sticks to the walls of capillaries causing obstruction of vessels. 
When this mechanism operates at the level of brain vessels, the loss of 
consciousness is the first symptom, but, if this form of cerebral malaria is not 
treated immediately, it is soon followed by death. 
 
Figure 4.1 The malaria cell cycle 
The treatment of malaria infections holds a important place in the history of 
natural product chemistry. In the 17th century the bark of Cinchona trees was 
used as the best tool to face infections of malaria, that was endemic in Africa, 
Asia but also in several parts of Europe and North America: this was the first 
specific treatment for malaria. Later, quinine (1), isolated from the Cinchona 
bark in 1820, was the first active principle isolated from a natural source 
employed to treat malaria disease; and, later again, malaria was the first 
human disease to be treated with a synthetic drug (methylene blue in 1891). 
In the course of 20th century, a series of effective synthetic antimalarial drugs 
have been developed: chloroquine (2), mefloquine (3), and pyrimethamine 
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(4) became the drugs of choice and contributed to the almost complete 
eradication of malaria from Europe and North America. 
 
The development of worldwide resistance of P. falciparum to the 4-
aminoquinoline chloroquine (first observed in the 1960s) as well as 
resistance to the antifolates pyrimethamine and cycloguanil, undermined the 
chemotherapy and prophylaxis of malaria. Two major breakthroughs of the 
past few decades have renewed the attack of scientists to this disease. The 
first is the complete sequencing of the genome of Plasmodium falciparum that 
is expected to provide useful information for the identification of new drug 
targets. The second is the discovery of artemisinin (5, qinghaosu): it is an 
endoperoxide sesquiterpene lactone, active principle of the sweet 
wormwood, Artemisia annua, an herbal remedy used in folk Chinese 
medicine. This molecule and its oil soluble (e.g. artemether, 6, and arteether) 
and water soluble (e.g. artesunate, 7, and artelinate) semi-synthetic 
derivatives (Figure 4.3) have shown excellent efficacy against chloroquine-
resistant Plasmodium strains and are becoming increasingly used, especially 
in combination with traditional antimalarials (e.g. mefloquine, 3).  
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Despite intensive efforts to control malaria, the disease continues to be one of 
the greatest health problems faced by Asian, African and South American 
countries.24 According to WHO estimates, about 207 million clinical cases of 
malaria occurred in 2012, maintaining its deplorable ranking as one of the 
top killer diseases.25 The failure to control malaria in these areas is explained 
by the emergence and spread of resistance to first-line antimalarial drugs and 
recently to artemisinin (5) too, cross-resistance between the members of the 
limited number of drug families available, and in some areas, multi-drug 
resistance.26 In addition, the prevalent spreading of the disease to poor 
countries has suggested to many pharmaceutical companies to categorize 
malaria as a low priority.  
Among the drugs currently used for malaria case management, artemisinin 
based combination therapies (ACTs)27 and primaquine28 have impact on 
malaria transmission, by reducing the infectiousness of individuals to 
mosquitoes.29 Clinical evidence indicate that artemisinin derivatives’ activity 
is restricted to developing gametocytes whereas primaquine is able to hit 
also the circulating mature gametocytes.30 On the basis of the drugs' 
respective activity profiles, WHO recommends the addition of  a single dose 
of primaquine to the ACT treatment course for the management of 
uncomplicated Plasmodium falciparum malaria in areas threatened by 
artemisinin resistance and/or in pre-elimination phase.31 However, a viable 
alternative to primaquine is urgently needed, considering that this compound 
can provoke hemolytic anemia in patients with glucose-6-phosphate 
dehydrogenase deficiency.32 Among the various available approaches, the 
exploration of empirically effective and chemically characterized antimalarial 
plants represents a valid strategy for the discovery of new druggable 
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compounds active against gametocytes and/or sporogonic stages for the 
development of multi-stage combination medicines.  
4.1.2 The antimalarial potential of plants 
In many African countries where malaria is endemic and in particular in rural 
areas where access to modern health care facilities is often hindered, 
traditional practices to cure or prevent malaria and other diseases still play 
an important role. People give preference to the use of herbal remedies for 
several reasons including:  easier access, lower cost, lack of awareness about 
modern drugs and belief that the use of traditional medicine is more safe and 
effective. Currently, there are several standardized anti-malarial 
phytomedicines which have obtained  official  approval for 
commercialization in various malaria endemic countries over the world, 
namely China, Ghana, India, Mali and Burkina Faso. Among few such products 
for which clinical research has been conducted, encouraging results were 
obtained with Qing hao (Artemisia annua, Democratic Republic of Congo 
trials), Totaquina (Cinchona spp, Multicountry trials) and Phyto-laria 
(Cryptolepis sanguinolenta, Ghana trial) showing a parasite clearance at day 5 
to 7 after treatment of 70  100%,  92  100% and 100%, respectively, hence 
supporting their use as complementary tools to the conventional anti-
malarial interventions  or as alternative treatments in the absence of 
antimalarial drugs.33 
The multistage activity of artemisinin derivatives on asexual blood stages and 
early gametocytes,34 has encouraged researchers to explore molecules of 
plant origin seeking not only activity on parasite stages developing in the 
vertebrate host but also transmission blocking effects against the sporogonic 
stages developing in the mosquito vector. Recently, Lucantoni et al. 
demonstrated the in vivo transmission blocking property of azadirachtin A 
enriched formulation (NeemAzal®)  on P. berghei sporogonic development in 
Anopheles stephensi mosquitoes.35 The commercial Azadirachta indica seed 
extract36 was found to completely block parasite development in the vector. 
Azadirachtin A has been shown to inhibit the formation of flagellate 
microgametes from microgametocytes with an IC50 of 3.5 µM,37 suggesting 
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that microgametogenesis is a main target process of NeemAzal® transmission 
blocking action. The transmission blocking activity of this Azadirachtin A rich 
neem product was recently confirmed in the human parasite P. falciparum by 
studies conducted in Burkina Faso on field isolates.38 
In sub-Saharan countries, including Ethiopia, the leaf of Vernonia amygdalina 
Del. is used for the treatment and prevention of malaria.39 The anti-
plasmodial activity of this small shrub of the Asteraceae family has been 
confirmed by several in vitro40 and in vivo studies.  
Several secondary metabolites have been isolated and characterized from V. 
amygdalina leaves such as sesquiterpene lactones, steroidal saponins 
(vernoniosides) and flavonoids (luteolin and its glycosides). The class of 
sesquiterpene lactones is probably the most peculiar of this plant and it 
includes the highly oxygenated derivatives vernolide,41 vernodalol,41 
vernodalinol,42 epivernodalol,43 vernodalin and vernomygdalin.44 Vernolepin, 
belonging to the same chemical class, has been isolated from the dried fruit of 
the plant.45 Vernolide and vernodalin exhibited IC50 of 1.87 and 0.52 µg/ml, 
respectively, against P. falciparum blood stages in vitro.46 In another study, 
IC50 values of  8.4, 4.0, 4.2 and 11.4 µg/ml  were obtained for vernolide, 
vernodalin, vernodalol and hydroxyvernolide, respectively.47 
On the basis of the above illustrated broad knowledge available on V. 
amygdalina as an antimalarial plant -from its evidenced appreciable clinical 
efficacy to the partially characterized activity profile of some secondary 
metabolite- we selected this plant as a valid candidate for investigation on 
potential inhibitors of Plasmodium transmission stages. 
4.1.3 Antimalarial activity of Vernonia amygdalina extracts 
Exploratory in vivo studies conducted with P. berghei ANKA strain and An. 
stephensi mosquitoes, revealed transmission blocking activity of 
V. amygdalina  aqueous (Ver-H2O) and ethanolic (Ver-EtOH) leaf extracts. An. 
stephensi females, fed on gametocytemic mice  treated with Ver- H2O at 500 
mg/kg and Ver-EtOH at 100 mg/kg, developed respectively 55 and 90% 
fewer oocysts compared to controls. 
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Methanol extract of V. amygdalina leaves was partitioned between water and 
EtOAc and this latter phase revealed interesting activity against the early 
stages of sporogonic development. Chormatographic fractionaction of this 
extract yielded 14 fractions, three of which proved to be active. (Table 4.1). 
Table 4.1 Inhibitory activity of ethylacetate phase fractions from V. amygdalina 
leaves against early sporogonic stages. 
Test agents Experiment‡ Mean ESS counts 
(95% CI)* 
Percentage inhibition 
of ESS (95% CI) 
Fraction-11 
1 1  (0    2) 96.3  (92.2    100) 
2 0  100 
3 0  (0    1) 99.7  (99    100) 
4 1  (0    1) 99.7  (99.4    100) 
5 0 100 
Fraction-12 
1 0 100 
2 1  (0    2) 95.1  (85.6    100) 
3 0  (0    1) 99.7  (99    100) 
4 1  (0    2) 99.7  (99.1    100) 
5 0  (0    1) 99.8  (99.3   100) 
Fraction-13 
1 0  100  
2 0  (0    1) 97.6  (92.8    100) 
3 0 100  
4 0  (0    1) 99.8  (99.5    100) 
5 1  (0    2) 99.5  (98.5    100) 
Solvent control  
(0.2% DMSO) 
1 27  (22    33) 
 
2 14  (9    19) 
 
3 96  (85    106) 
 
4 219  (198    240) 
 
5 135  (111    158) 
 
 
Fractions from ethylacetate phase were tested at 50 µg/mL concentration. 
Data are presented as mean early sporogonic stages (ESS) counts calculated from triplicate 
wells and percentages of ESS inhibition referred to solvent control.  Both parameters are 
presented with 95% confidence intervals (95% CI). 
‡Each number represents one experiment conducted with gametocytaemic blood from a 
different mouse. 
*Mean ESS counts are rounded to the nearest whole number. 
Chemical analysis of these fractions allowed isolation and identification of 
the two compounds most likely responsible for the transmission blocking 
activity observed, namely vernodalol and vernolide, whose structures were 
identified by comparison with spectroscopic data in the literature.41 These 
two molecules are sesquiterpene lactones belonging to the structural classes 
of germacranolides (vernolide) and elemanolides (vernodalol).  
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Tested as pure compounds, vernodalol and vernolide exhibited moderate to 
low activity in the in vitro ookinete development assay (ODA) (Table 4.2). At 
a concentration of 50 M (19.6 g/mL) vernodalol inhibited early sporogonic 
development (ESS) by 70-90%, while vernolide at the same concentration 
(50 M, 18.1 g/mL) reduced ESS by 9–33%.  
Table 4.2 Impact of vernolide and vernodalol on the development of early 
sporogonic stages in vitro 
Test 
compounds 
Experiment‡ 
Mean ESS counts  
(95% CI)* 
Percentage 
inhibition of ESS 
(95% CI) 
Vernodalol 
1 24  (21    26) 79.3  (77.3    81.4) 
2 12  (8   16) 89.7  (86.4    92.9) 
3 92  (77   107) 69.3  (64.3    74.3) 
Vernolide 
1 103  (90   115) 9.4  (0    20.5) 
2 79  (63    95) 30.6  (16.7    44.5) 
3 201  (182    220) 33  (26.6    39.3) 
Solvent control  
(0.2% DMSO) 
1 113  (93    134) 
 2 114  (97   132) 
 3 300 (284    317) 
 
Compounds were tested at a concentration of 50 M. 
‡Each number represents one experiment conducted with gametocytaemic blood from a 
different mouse; ESS counts are means from sextuplicate wells. 
*Mean ESS counts are rounded to the nearest whole numbers 
In line with these data, V. amygdalina AcOEt fractions composed of almost 
only vernodalol and vernolide showed evident inhibitory activity in the ODA. 
Fraction 11 (about 91% vernolide), fraction 12 (about 50% vernolide + 50% 
vernodalol) and fraction 13 (about 85% vernodalol) suppressed ESS by 95 – 
100% when tested at 50 g/mL (corresponding to amounts of 42 – 50 g/mL 
of vernolide, vernodalol or vernolide + vernodalol). 
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A relatively stronger activity than expected for its vernodalol and vernolide 
content, was observed with the AcOEt phase preparation. This finding may 
indicate the presence of other bioactive constituents in the EtOAc phase, 
having a direct effect on ESS or influencing the activity of vernolide and 
vernodalol. 
Differential counting of zygotes and ookinetes indicated that Ver-EtOH 
interfered with  processes  preceding zygote formation (Figure 4.2). At the 
highest tested concentration (50 g/mL), however, an impact on subsequent 
ookinete maturation was also observed. Interestingly, this was not the case 
with pure vernolide and vernodalol or with fractions 11 to 13, consisting 
almost entirely of these two compounds, an observation suggesting that the 
two sesquiterpene lactones may interfere with the first processes of 
sporogonic development, namely gametogenesis and/or macrogamete 
fertilization.  
 
Figure 4.2 Proportion of mature ookinetes with respect to total early sporogonic 
stage.* 
*The test was conducted using ethanolic V. amygdalina leaf extract (Ver-EtOH) at different 
concentration and solvent control (dimethyl sulfoxide). Each bar in the graph refers to 
readings from 3 and 6 microplate wells in experiment 1 and 2, respectively. 
Exflagellation tests performed with vernodalol and Ver-EtOH allowed to 
further narrow down the possible target stages. Both the compound and the 
extract, tested at 50 M and 50 g/mL respectively, did not interfere with 
microgamete formation in vitro, suggesting that the processes targeted by 
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V. amygdalina transmission blocking components are mainly 
macrogametogenesis and/or macrogamete fertilization.  
Vernolide and vernodalol have been reported to exhibit moderate activity 
also on asexual blood stages46-47 inhibiting P. falciparum asexual forms by 
50% at a concentration of 1.87  8.4 M  and 4.2 M, respectively. This multi-
stage activity of vernodalol and vernolide  raises  exciting  questions on 
modes and mechanisms of action of the two sesquiterpene lactones and 
research focused into this aspect may  lead to the discovery of novel 
multistage drug targets.  
The experiments conducted in Burkina Faso with P. falciparum field isolates 
allowed us to evidence the transmission blocking activity of V. amygdalina 
also against the human malaria parasite. An. coluzzii mosquitoes that had 
membrane-fed on gametocytemic blood treated with the vernolide and 
vernodalol-rich EtOAc fractions (fraction 11 and 13 respectively) were less 
infected and oocyst numbers in positive mosquitoes were reduced by about 
half. The membrane feeds were supplemented with the fractions at a dosage 
of 100 g/mL corresponding to vernolide and vernodalol equivalents of 
91.2 g/mL and 85 g/mL, respectively. The relatively high dosage needed to 
achieve a substantial reduction in  sporogonic development of P. falciparum, 
taken together with the moderate activity by the pure compounds observed 
in vitro on P. berghei, suggest that neither vernodalol nor vernolide possess 
the potency required for a drug candidate molecule. On the other hand, our in 
vivo experiments evidenced significant transmission blocking activity by the 
Ver-EtOH extract and the bio-guided fractionation studies revealed a 
relatively higher in vitro activity of extracts compared to that of the pure 
compounds,  suggesting that the development of a phytomedicine based on 
vernodalol and vernolide enriched standardized extract may be a more 
appropriate strategy to pursue.  
Artemisinin derivatives have been demonstrated to possess activity against 
P. falciparum gametocytes in vitro48 and in clinical trials27, shortening the 
period of gametocytes circulation in patients treated with ACTs49 and thus 
decreasing the infection rates of blood seeking mosquitoes. In the current in 
vivo study, Ver-H2O administered to mice at 500 mg/kg was found to reduce 
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macrogametocyte densities by about 50%. A decrease in microgametocyte 
numbers was also noticed, reaching significance in one of the two replicates 
carried out. Since Ver-H2O did not exhibit in vitro activity on early sporogonic 
stages, but still reduced oocyst densities in mosquitoes when administered to 
females in vivo through an infectious blood meal, the observed transmission 
blocking effect might be attributed to the gametocytocidal activity of Ver-
H2O.   
Considering the diverging gametocyte biology of  P. falciparum and 
P. berghei50, a validation of the activity of extracts on P. falciparum 
gametocytes is the next step to be undertaken. If confirmed, subsequent bio-
guided fractionation studies may allow the identification of new 
gametocytocidal compounds.  
The cytotoxic properties of V. amygdalina extracts and compounds have been 
assessed on various cell lines: IC50 values vary widely with the compounds 
and type of cell lines used (Table 4.3). 
Table 4.3 Activity of V. amygdalina extracts, fractions and pure compounds on cell 
viability of a human colon cancer and endothelial cell line. 
Test agents 
IC50 (95% CI) 
HCT116 EA.hy 926 
Leaf extracts (g/mL)    
Ver-EtOH 3.66  (3.41    3.96) 9.46  (8.64    10.36) 
Ver-MeOH 8.09  (7.54    8.67) 16.94  (15.55    18.46) 
Ver-H2O 64.34 (58.75    70.53) 76.21  (58.09    100.00) 
Fractions from MeOH extract 
(g/mL)     
Fraction 11 0.17  (0.15    0.18)  0.42  (0.39    0.45) 
Fraction 12 0.33  (0.3    0.37) 1.13  (0.97    1.31) 
Fraction 13 2.41  (2.29    2.53) 4.52  (4.23    4.82) 
Fraction 14 3.86  (3.62    4.12) 7.69  (7.10    8.32) 
Molecules from fractions (M)   
Vernolide 1.49  (1.38    1.61) 3.18  (2.97    3.4) 
Vernodalol 4.97  (4.78    5.17) 7.1  (6.51    7.74) 
Each value represents the mean of two experiments carried out in quadruplet wells.  
HCT 116=Human colon carcinoma cell line, EA.hy 926= Human (non-tumor) endothelial cell 
line.  
Ver-EtOH, Ver-MeOH, and Ver-H2O stands for ethanolic, methanolic and aqueous extract of 
V. amygdalina leaves. 
95% CI = 95% confidence interval 
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However, given the interesting multi-stage activity of vernodalol and 
vernolide, the molecules still are worth to be considered for structure-
activity relationship studies aimed at designing compounds with reduced 
toxicity and enhanced activity against ESS and asexual blood stage parasites. 
Also, the compounds might be utilized as tools to investigate potential drug 
targets expressed in multiple life cycle stages.  
4.2 MICHAEL-RELATED BIOACTIVITY OF SESQUITERPENES 
LACTONES  
The organic extract obtained from the leaves of an Ethiopian specimen of V. 
amygdalina proved to be a rich source of sesquiterpene lactones. From the 
detailed chemical analysis of the EtOAc phase, we isolated five known (8-12) 
molecules and three new members of this family, namely methylvernolide 
(13), deoxyvernodalol (14) and vernomygdalin (15). The availability of these 
compounds provided the opportunity to shed light on the molecular 
mechanisms underlying the anti-inflammatory and anticancer activities of 
the  extract of Vernonia amygdalina.  
 
There is growing awareness that electrophilic natural products interact with 
their biological targets according to a “dock and lock” mechanism, where 
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shape complementarity is important to position the reactive site(s) of a 
covalent ligand in an optimal orientation for thiol trapping. Given the poly-
electrophilic nature of the major sesquiterpene lactones we had isolated, it 
was important to identify the most reactive thiophilic site within each 
compound and to rank them in order of reactivity using the cysteamine 
assay, a straightforward method to identify Michael acceptors, recently 
published by my research group.51 By comparing these data with those of 
bioassays on targets sensitive to thiol trapping and involved in inflammation 
like the transcription factors NF-kB, STAT3 and Nrf2, the relative 
contribution of shape and reactivity to the bioactivity of these compounds 
could be dissected.   
4.2.1 Structure elucidation of new sesquiterpenes lactones 
Repeated chromatographic purification of the organic phase of V. amygdalina 
methanol extract, yielded the known compounds vernolide (8),44 
dihydrovernolide (10),52 hydroxyvernolide (11),53 vernodalol (9),54 and 
methoxyvernolepin (12),54 identified on the basis of the comparison of their 
spectral data with those reported in the literature,  and the new 
methylvernolide (13), deoxyvernodalol (14), and vernomygdalin (15). 
Methylvernolide (13), C20H24O7 by HRMS, was easily identified as the 14-O-
methyl derivative of the highly oxygenated germacranolide vernolide (8). 
The 1H NMR spectrum of 13 (CDCl3) was practically superimposable to that 
of 8, with the single exception of the replacement of the OH-14 signal at δH 
4.95 with a methyl singlet resonating at δH 3.91. The location of this group 
was supported by the HMBC cross-peak  of the methyl singlet with C-14 (δC 
99.2).     
Analogously, the relationship between deoxyvernodalol (14), C20H24NaO7 by 
HRMS, and the acylated elemanolide vernodalol (9) was suggested by the 
close similarity between their 1H NMR spectra. Since the proton resonances 
attributable to the sesquiterpene core were practically coincident for the two 
compounds, the differences must be located in the O-8 acyl group. A methyl 
singlet (δH 1.86) and a sp2 methylene (δH 5.73 and 5.53, both bs, δC 126.4, 
associated by HSQC) accounted for the five proton signals of this acylating 
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moiety and its 2-methyl-propenoyl structure was supported by the HMBC 
cross-peaks of all these proton signals with both C-2' (δC 144.4) and C-1' (δC 
167.4). Similarly, the attachment of the acyl group at C-8 was secured by the 
HMBC cross-peak H-8/C-1'. Thus, in agreement with its molecular formula, 
the new compound 14 must differ from vernodalol for a deoxygenation at C-
3'.  
Vernomygdalin (15) was isolated in minute amounts as a colorless 
amorphous solid with molecular formula C15H18O5 by HRMS. 1H and 13C NMR 
spectra of 15 (CDCl3) were suggestive of an elemanolide sesquiterpene of the 
vernodalol family. The COSY spectrum arranged most of the proton signals 
within a large spin system (Figure 4.3) encompassing five methines 
(including two oxymethines), a diastereotopic methylene and a methyl 
doublet (δH 1.46). The remaining proton resonances belonged to a 
monosubstituted double bond, an uncoupled conjugated sp2 methylene (δH 
6.75, bs; 5.76, bs) and an isolated oxymethylene (δH 4.42 and 4.24, both d). 
Having associated all the proton resonances to those of the directly attached 
carbon atoms through the 2D HSQC spectrum, we used the HMBC experiment 
to join the above different moieties. HMBC cross-peaks of H2-14, H2-15 and H-
1 (red arrows in Figure 4.3) built up a vernodalol-type bicyclic system. The 
two remaining unsaturation degrees implied by molecular formula were 
accounted by a γ-lactone ring, as clearly indicated by the HMBC cross-peaks 
of both H3-13 and H-6 with C-12 (violet arrows in Figure 4.3). The network of 
ROESY correlations of vernomygdalin (15) (Figure 4.3) indicated a relative 
configuration identical to that of vernodalol for parallel stereogenic centers 
and suggested the α orientation of the methyl group at C-11.    
 
 
Figure 4.3 Selected 2D NMR correlations of vernomygdalin (15). left: COSY 
(boldened lines) and HMBC correlations (arrows); right: ROESY correlations. 
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4.2.2. Michael related bioactivity: NF-Kb and STAT3 inhibition. 
Although the eight sesquiterpene lactones isolated during this study belong 
to two different structural families, germacranolides of the vernolide-type (8-
10-11-13) and elemanolides of the vernodalol-type (9-12-14-15), they share 
the common feature of a single (as in 10 and 15) or multiple (three in 9 and 
14) potential Michael acceptor sites in their structures.  
Michael acceptors are generally discarded during drug discovery processes 
on the basis of their tendency to form off-target covalent linkages, a reactivity 
considered potentially toxic. However, this bias underestimates the 
incredible biological potential of selective thiol-reactive Michael acceptors, 
which have been demonstrated to target a number of important and 
druggable pathways. For example, protein kinase inhibition,55 TRPA1 
activation,51-56 PPARγ modulation,57and NF-ĸB inhibition58 have all been 
related to thia-Michael acceptor structural motifs. The multi-faceted anti-
inflammatory and anticancer bioactivity of the food plant compound 
curcumin well exemplifies the pharmaceutical relevance of these 
compounds.57 
The availability of Vernonia poly-electrophilic sesquiterpene lactones made it 
possible to evaluate the ability of the NMR-based cysteamine assay51 to 
discriminate their reactivity as thiol trapping agents. In this assay, the 
substrate is dissolved in DMSO-d6 and cysteamine (1.2 equivalents) is added 
directly in the NMR tube: a positive assay is evidenced by the immediate 
marked reduction or disappearance of the carbonyl conjugated double bond 
signals. The use of only 1.2 equiv of cysteamine allows to get information on 
the reactivity order in molecules containing multiple acceptor sites, while 
competition experiments with different substrate and sub-stoichiometric 
amounts of cysteamine make it possible to rank them in terms of reactivity.  
Vernolide (8) and vernodalol (9) exemplify the poly-electrophilic nature of 
the Vernonia exomethylene lactones, and were chosen for these experiments. 
The 1H NMR spectra of these compounds were first registered in DMSO-d6, 
fully assigned by 2D NMR experiments, and then re-analyzed 15 min after 
addition of 1.2 equiv of cysteamine. Both vernolide and vernodalol gave a 
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single major product of addition (Figure 4.4), but the regiochemistry of 
addition was surprisingly different.  
Thus, vernolide (8) underwent exclusive addition of cysteamine to the 
exomethylene γ-lactone group, with no evidence of reaction at the α,β-
unsaturated ester moiety, the epoxide group or the semiacetalized aldehyde 
function. Conversely, vernodalol (9) reacted selectively at the O-8 acyl group, 
with the other electrophilic sites (the exomethylene δ-lactone and the 
acryloyl moiety) remaining unscathed. 
 
Figure 4.4 Results of the cysteamine assay for vernolide (8) and vernodalol (9). The 
reactive Michael acceptor moiety is marked in red. 
These results, while validating the ability of the cysteamine assay to identify 
the most reactive site in polyfunctional thiol trapping agents, provide solid 
evidence that electrophilic sesquiterpene lactones are an heterogeneous 
group of compounds in terms of reactivity sites, that goes substantially 
beyond the presence of a common 11,13-exomethylene group.  
In a comparative experiment, an equimolar mixture of vernolide (1) and 
vernodalol (5) was treated with an amount of cysteamine corresponding to 
the trapping of a single electrophilc group. The 1H NMR spectrum recorded 
after 15 min showed the preferential reaction of vernolide, as clearly 
evidenced by the selective decrease of the signals of its exomethylene-γ-
lactone protons (H-13a,b δ 6.06 and 5.58) over the signals of the reactive acyl 
group of vernodalol (H-4'a,b δ 6.00 and 5.78) (Figure 4.5). This comparative 
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experiment clearly establishes a ranking in the reactivity, identifying 
vernolide as the most reactive compound.   
 
Figure 4.5 Comparative cysteamine assay of a ca. equimolecular mixture of 
vernolide (8) and vernodalol (9). A) reference mixure B) spectrum obtained after 
the addition of a stoichiometric amount (1.0 equivalent) of cysteamine.  
The red arrows indicate the signals of the exomethylene-γ-lactone protons of vernolide. 
Thia-Michael acceptor reactivity has been related to the modulation of a 
number of important biological targets.57-59 Among the thiol-trapping 
sensitive end points, the transcription factors NF-κB, STAT3, and Nrf2 have 
been described to play a significant role in regulating the expression of genes 
coding pro-inflammatory cytokines and in the pathogenesis of human 
disorders characterized by a chronic inflammatory component, including 
cancer.60 Thus, we evaluated the sesquiterpene lactones of V. amygdalina for 
inhibition of the pro-inflammatory transcription factors NF-κB and STAT3 
and activation of the anti-inflammatory transcription factor Nrf2, which is 
considered the “master regulator” of the antioxidant response (Table 4.8). 
The anti-NF-κB activity was measured in 5.1 cell line activated with TNFα; 
the anti-STAT3 activity was measured in LNCaP cells activated with IFN-γ, 
and Nrf2 activation was investigated in the HaCaT-ARE-Luc cell line. The 
cytotoxic activity was measured in the prostate cancer cell line DU145. 
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Table 4.4 Activity of V. amygdalina sesquiterpenoids on inhibition of NF-κB and 
STAT3, activation of Nrf2 and cytotoxicity in DU145 cells. 
Compound NF-κB 
IC50 (μM) 
STAT3 
IC50 (μM) 
Nrf2 
EC50 (μM) 
Cytotoxicity 
IC50 (μM) 
Vernolide (8) 6.3 ± 2.1 6.1 ± 3.1 0.7 ± 0.3 40.1 ± 4.3 
Dihydrovernolide (10) > 50 > 50 > 50 > 50 
Vernodalol (9) 18.2 ± 2.6 20.4 ± 3.8 3.2 ± 1.8 46.8 ± 5.8 
Deoxyvernodalol (14) 9.0 ± 3.2 12.3 ± 4.1 5.2 ± 2.3 > 50 
Methoxyvernolepin (12) > 50 > 50 > 25 > 50 
 
Vernolide (8) and deoxyvernodalol (14), and to a lesser extent vernodalol 
(9), showed a marked inhibitory activity on STAT3/NF-B; deoxyvernodalol 
(14) and vernodalol (9) showed a good Nrf2 activation evidencing also a 
good correlation between this activity and cytotoxicity. It is possible that 
STAT3/NF-B inhibitory activity of vernolide (8) results in an increase in 
oxidative stress that induces cytotoxicity. In this sense, the ability of 
deoxyvernodalol (14) and vernodalol (9) to induce the expression of Nrf2-
dependent antioxidant genes may counteract this oxidative stress and 
prevent the cytotoxicity associated to vernolide (8). The structurally related 
analogues dihydrovernolide (10) and methoxyvernolepin (12) were 
practically inactive on the same pharmacological endpoints.  
These pharmacological results are in striking agreement with the outcomes 
of the NMR-based cysteamine assay. Indeed, the inactive dihydrovernolide 
(10) differs from the active vernolide (8) only for the lack of the conjugated 
exomethylene, selected as preferential thia-Michael acceptor by the 
cysteamine assay. Similarly, the inactive methoxyvernolepin (12) differs 
from the active vernodalol (9) only for the lack of the O-8 acyl group, the 
moiety positive in the cysteamine assay, although two other potentially 
reactive α,β-unsaturated esters are still present in its structure. 
In addition to the pro-inflammatory activity, NF-κB and STAT3 are also 
involved in the aberrant cell cycle progression of cancer cells. Since vernolide 
(8) qualified as the most active NF-κB and STAT3 inhibitor in our assays, we 
studied its effect on cell cycle progression in the DU145 cell line that 
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expresses constitutive activation of both transcription factors. In this cell line 
we found that vernolide is cytotoxic and arrested the cell cycle at the S phase, 
a clear example of antitumor activity related to NF-κB and STAT3 inhibition 
(Figure 4.6). 
 
 
Figure 4.6 Vernolide induces cell cycle arrest*. 
* A) DU145 cells were incubated with vernolide (1) for 48 h at the indicated 
concentrations and the cell viability was measured by the MMT assay; insert shows 
that D145 cells express STAT3 and NF-B/p65 constitutively phosphorylated. B) 
DU145 cells were treated with vernolide (8) for 24 h and the cell cycle analyzed by 
flow cytometry. The percentage of cells in the phases S and G2M are indicated. 
Taken together, these data show that, due to its high concentration and 
superior activity, vernolide should be considered the major anti-
inflammatory constituent of extracts from V. amygdalina.22 Given the role of 
the investigated transcription factors in many steps of cancer initiation and 
progression, their inhibition can be also related to prevention and treatment 
of cancer, thus providing a molecular rationale for the anticancer activity 
reported for V. amygdalina extracts.22 Moreover we evidenced the differential 
bioactivities of deoxyvernodalol (14) on STAT3/NF-B and Nrf2 signaling 
pathways, and this compound qualifies as an interesting anti-inflammatory 
and antioxidant agent that could be used for the treatment of chronic 
inflammatory disorders. 
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4.3 CONCLUSIONS 
Previously published works and the present study demonstrate that 
V. amygdalina leaves contain molecules affecting multiple stages of 
Plasmodium, evidencing its potential for drug discovery and for the 
development of standardized V. amygdalina based phytomedicines. On the 
identified hit molecules, primarily vernodalol, chemical or functional group 
modification is recommended to generate a druggable sesquiterpene lactone 
compound with enhanced activity against the blood and sporogonic stages of 
the malaria parasite and reduced off-target activities. In addition, the 
development of a multistage phytomedicine, exhibiting both anti-blood stage 
as well as transmission blocking properties and designed as a preventive 
treatment to complement existing malaria control tools appears a challenging 
but feasible goal. 
The sesquiterpene lactones V. amygdalina provided also the opportunity to 
validate the cysteamine assay as a tool to investigate thiophilicity and to 
build a sort of Michael-oma profile of a certain class of compounds, 
identifying the most reactive site in polyfunctional compounds and ranking 
them in terms of reactivity. In the pair of compounds investigated (vernolide 
and vernodalol), a correlation between reactivity and bioactivity was found 
in all three inflammatory-related end-points investigated. This should, 
however, be validated using larger databases of sesquiterpene lactones, since 
in other classes of Michael acceptors like curcuminoids no direct correlation 
between reactivity and bioactivity was found.57 
4.4 EXPERIMENTAL SECTION 
4.4.1 Plant material, extraction and isolation 
V. amygdalina Del. (Asteraceae) leaves were collected in the area of Karat 
town, located in Konso district, i.e., 600 km south of Addis Ababa, Ethiopia, 
after the rainy season (October 2011). A leaf specimen was used for 
taxonomic identification, and authenticated by Mr. Melaku Wondafrash, a 
plant taxonomist. A voucher specimen was deposited (Solomon-0l) at the 
National Herbarium, Addis Ababa University, Ethiopia. 
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V. amygdalina leaves were air-dried at room temperature in the shade and 
ground using a blender. Ground material (50 g) was macerated in ethanol 
(EtOH) for 24 h and filtered with filter paper (Whatman® no.1). Ethanol was 
removed using a rotary evaporator  at 40 °C under reduced pressure. The 
extract was further concentrated by freeze drying and stored at -20 °C until 
use. To  prepare the aqueous extract (Ver-H2O), 50 g of ground V. amygdalina 
leaves were macerated in distilled water for 24 h, then filtered and freeze 
dried. The percent yields of the aqueous and ethanol extractions were 14% 
and 8%, respectively. 
To identify secondary metabolites responsible for transmission blocking 
activity, bio-guided fractionation was employed on a methanol (MeOH) 
extract of V. amygdalina leaves. Briefly, 450 g of leaf powder  was macerated 
in  MeOH for 24 h, to obtain a dried MeOH extract (34.5 g, yield 7.6%). A 
portion of this extract (27.9 g) was then partitioned, first between water and 
ethyl acetate (EtOAc), and then between water and butanol (BuOH), to get 
the following phases: EtOAc (14.3 g), BuOH (4.9 g) and H2O (7.9 g). The EtOAc 
phase was selected for bioassay guided fractionation. It was subjected to 
medium pressure liquid chromatography (MPLC) over a column packed with 
silica gel (230-400 mesh) and eluted with the following solvent gradient of 
increasing polarity: n-hexane, to n-hexane:EtOAc (9:1), n-hexane: EtOAc 
(4:1), n-hexane: EtOAc (7:3), n-hexane: EtOAc (3:2), n-hexane: EtOAc (1:1), n- 
hexane: EtOAc (7:11), n-hexane: EtOAc (1:4), EtOAc, EtOAc:MeOH (1:1) and 
finally MeOH. A total of 40 eluates of 250 mL each were collected and 
combined on the basis of thin layer chromatography behavior, to get 14 
fractions which were then tested for anti-plasmodial activities in vitro. 
The  active fractions (fr. 11  14) were further purified by high performance 
liquid chromatography (HPLC) on a Knauer apparatus equipped with a 
refractive index detector and LUNA (5µ, 250 × 4 mm Phenomenex) SI60 or 
Kinetex (2.6µ, 100 × 4.60 mm Phenomenex) C18 columns. Fraction 11 was 
separated by HPLC (n-hexane/EtOAc 75:25, flow 0.8 mL/min) to get pure 
vernolide (8, 225.3 mg), methylvernolide (13, 1.5 mg), dihydrovernolide (10, 
5.5 mg) and deoxyvernodalol (14, 3.4 mg). Fraction 12 was separated by 
HPLC (n-hexane/EtOAc 6:4, flow 0.7 mL/min) to get pure hydroxyvernolide 
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(11, 1.2 mg) and vernomygdalin (15, 0.8 mg). Fraction 13 was separated by 
HPLC (n-hexane/EtOAc 1:1, flow 0.8 mL/min) to obtain pure 
methoxyvernolepin (12, 6.5 mg) and vernodalol (9, 165.5 mg).  
4.4.2 Spectroscopic data for isolated compounds. 
Methylvernolide (13): colorless amorphous solid; [α]D + 150.0 (c 0.10, 
CHCl3); 1H NMR (CDCl3, 700 MHz): δ 6.38 (1H, d, J = 2.6 Hz, H-13a), 6.16 (1H, 
bd, H-4'a), 5.99 (1H, d, J = 2.6 Hz, H-13b), 5.73 (1H, bd, H-4'b), 5.73 (1H, 
overlapped, H-8), 5.59 (1H, d, J = 7.7 Hz, H-5), 5.25 (1H, t, J = 10.0 Hz, H-6), 
4.62 (1H, d, J = 14.2 Hz, H-15a), 4.56 (1H, s, H-14), 3.91 (3H, s, OCH3-14), 3.69 
(1H, d, J = 14.2 Hz, H-15b), 3.09 (1H, m, H-7), 2.72 (1H, dd, J = 11.3, 3.99 Hz, 
H-1), 2.67 (1H, d, J= 14.5 Hz, H-9a), 2.42 (2H, m, H2-3), 2.32 (1H, m, H-2a), 
1.98 (3H, s, H-3'), 1.69 (1H, m, H-2b), 1.42 (1H, dd, J = 14.5, 10.7 Hz, H-9b); 
13C NMR (CDCl3, 175 MHz): δ 169.4 (C-12), 167.2 (C-1'), 143.7 (C-4), 135.7 
(C-2'), 134.9 (C-11), 128.8 (C-5), 127.2 (C-4'), 126.1 (C-13), 99.2 (C-14), 77.4 
(C-6), 70.7 (C-8), 66.4 (C-1), 64.3 (C-15), 58.8 (C-10), 55.2 (OCH3-14) 51.9 (C-
7), 41.3 (C-9), 33.4 (C-3), 22.7 (C-2), 18.3 (C-3'). (+) ESI-MS m/z 399 [M + 
Na]+. HR-ESIMS: m/z 399.1428, calcd. for C20H24NaO7 399.1420. 
Deoxyvernodalol (14): colorless amorphous solid; [α]D + 102.7 (c 0.10, 
CHCl3); 1H NMR (CDCl3, 700 MHz): δ 6.65 (1H, bs, H-15a), 6.34 (1H, bs, H-
13a), 6.01 (1H, bs, H-15b), 5.76 (1H, bs, H-13b), 5.73 (1H, bs, H-4'a), 5.69 (1H, 
dd, J = 18.1, 11.6 Hz, H-1), 5.53 (1H, bs, H-4'b), 5.31 (1H, ddd, J = 11.63, 4.8, 
4.8 Hz, H-8), 5.25 (1H, dd, J = 18.1, 1.0 Hz, H-2a), 5.23 (1H, dd, J = 11.6, 1.0 Hz, 
H-2b), 4.69 (1H, d, J = 12.2 Hz, H-14a), 4.35 (1H, d, J = 12.2 Hz, H-14b), 4.11 
(1H, dd, J = 11.3, 10.4 Hz, H-6), 3.77 (3H, s, OCH3-12), 2.74 (1H, t, J = 11.3 Hz, 
H-7), 2.50 (1H, bd, J = 10.4 Hz, H-5), 1.86 (3H, s, H-3'), 1.50 (1H, m, H-9a), 1.30 
(1H, m, H-9b); 13C NMR (CDCl3, 175 MHz): δ 169.6 (C-12), 167.4 (C-1'), 166.6 
(C-3), 144.6 (C-1), 144.4 (C-2'), 141.5 (C-11), 136.4 (C-15), 135.3 (C-4), 130.7 
(C-13), 126.4 (C-4'), 117.7 (C-2), 73.5 (C-14), 72.6 (C-8), 71.5 (C-6), 57.0 (C-
7), 54.1 (OCH3-12), 54.0 (C-5), 42.5 (C-10), 40.7 (C-9), 18.2 (C-3'). (+) ESI-MS 
m/z 399 [M + Na]+. HR-ESIMS: m/z 399.1413, calcd. for C20H24NaO7 399.1420. 
Vernomygdalin (15): Colorless amorphous solid; [α]D + 6.5 (c 0.10, CHCl3); 
1H NMR (CDCl3, 700 MHz): δ 6.75 (1H, bs, H-15a), 5.96 (1H, bs, H-15b), 5.72 
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(1H, m, H-1), 5.29 (1H, overlapped, H-2a), 5.26 (1H, overlapped, H-2b), 4.42 
(1H, d, J = 11.6 Hz, H-14a), 4.24 (1H, d, J = 11.6 Hz, H-14b), 3.95 (1H, 
overlapped, H-8), 3.93 (1H, overlapped, H-6), 2.87 (1H, d, J = 12.1 Hz, H-5), 
2.61 (1H, m, H-11), 1.97 (1H, dd, J = 14.0, 4.8 Hz, H-9a), 1.86 (1H, m, H-7), 
1.64 (1H, dd, J = 14.0, 4.8 Hz, H-9b), 1.46 (3H, d, J = 5.3 Hz, H-13) ppm; 13C 
NMR (CDCl3, 175 MHz): δ 13C NMR (CDCl3, 175 MHz): δ 177.7 (C-12), 163.4 
(C-3), 140.2 (C-1), 136.0 (C-15), 130.5 (C-4), 116.6 (C-2), 81.7 (C-6), 71.4 (C-
14), 68.8 (C-8), 56.9 (C-7), 46.6 (C-5), 43.2 (C-9), 42.1 (C-10), 41.6 (C-11), 
14.1 (C-13)ppm. (+) ESI-MS m/z 301 [M + Na]+. HR-ESIMS: m/z 301.1060, 
calcd. for C15H18NaO5 301.1052. 
4.4.3 Cysteamine assay 
In a standard 5 mm NMR tube (Armar Chemicals), vernolide (8) or 
vernodalol (9) (ca. 5 mg) was dissolved in 500 μL DMSO-d6, and the 
spectrum was registered. Cysteamine (1.2 mol. equivalents) was next added, 
and the spectrum was re-registered ten minutes after the addition. A positive 
assay was evidenced by the disappearance of the carbonyl conjugated double 
bond signals of the substrate. Comparative experiments of reactivity were 
carried out by treating roughly equimolar amounts of vernolide (8) and 
vernodalol (9) with a stechiometric amount of cysteamine (1.0 equivalent) 
calculated on a single reactive site in only one of the two substrates. 
1H NMR assignment of vernolide (DMSO-d6): δ 6.06 (2H, bs, Ha-13, Ha-19),  
5.75 (1H, bs, Hb-19), 5.72 (1H, ovl, H-8), 5.59 (1H, ovl,  H-5), 5.58 (1H, bs, Hb-
13), 5.33 (1H, t, J=9.00 Hz, H-6), 4.54 (1H, bs, H-14), 4.50 (1H, d, J=13.67 Hz, 
Ha-15), 3.66 (1H, d, J=13.67 Hz, Hb-15), 3.22 (1H, m, H-7), 2.89 (1H, dd, 
J=11.30-4.00 Hz, H-1), 2.57 (1H, d, J=13.68 Hz, Ha-9), 2.34 (1H, m ovl, Ha-3), 
2.30 (1H, m ovl, Hb-3), 2.18 (1H, m, Ha-2), 1.88 (3H, s, H-18), 1.73 (1H, m, Hb-
2), 1.34 (1H, dd, J=13.68-10.00 Hz, Hb-9) ppm. 
1H NMR assignment of vernodalol (DMSO-d6): δ 6.36 (1H, s, Ha-15), 6.22 (1H, 
s, Ha-13), 6.00 (1H, s, Ha-4'), 5.95 (1H, s, Hb-13), 5.78 (1H, s, Hb-4'), 5.73 (1H, 
ovl, H-1), 5.68 (1H, s, Hb-15), 5.18 (1H, ovl, Ha-2), 5.12 (1H, ovl, Hb-2), 5.04 
(1H, m, H-8), 4.75 (1H, d, J=12.06 Hz, Ha-14), 4.34 (1H, d, J=12.06 Hz, Hb-14), 
4.03 (2H, ovl, H-3'), 3.80 (1H, dd, J=11.00-10.38 Hz, H-6), 3.67 (3H, s, H-20), 
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2.81 (1H, dd, J=11.00-10.38 Hz, H-7), 2.54 (1H, d, J=10.38, H-5), 1.87 (1H, bd, 
J=14.06 Hz, Ha-9), 1.55 (1H, dd, J=14.06-12.35 Hz, Hb-9) ppm. 
4.4.4 Cytotoxicity assays 
DU145 cells were seeded at a density of 104 cells/well in 96-well plates (200 
μL) and incubated with increasing concentrations of the compounds for 48 
hours. After that, 100 μL of MTT (5 mg/ml) from a mixture solution of MTT: 
DMEM (1:2) was added to each well, and cells were incubated for 4 h at 37 °C 
in darkness. Then the reaction was stopped, supernatant removed and 100 
μL of DMSO added to each well and incubated for 10 min in gentle shaking. 
Finally, the absorbance was measured at 550 nm using a TriStar LB 941 
(Berthold Technologies, GmbH & Co. KG). The absorbance of untreated cells 
was taken as 100% viability and the percentage of cellular viability 
calculated. 
4.4.5 Transcriptional assays 
 Anti-NF-κB activity was investigated in 5.1 cells, a validated “in vitro” model 
to study TNFα-induced NF-κB activation.29 5.1 cells were stimulated with 
TNFα (20 ng/mL) in the presence or absence of the compounds for 6 h. To 
study the activity of the compounds on the Nrf2 pathway we used the HaCaT-
ARE-Luc cell line.30 Cells were stimulated with the compounds for 6 h. To 
study STAT3 signaling, LNCaP cells were transiently transfected with the 
pTATA-TK-Luc plasmid that contains four copies of the STAT-binding site. 
Transient transfections were performed with Rotifect (Carl Roth GmbH, 
Karlsruhe, Germany) according to the manufacturer’s instructions, and 24 h 
after transfection, cells were pre-incubated with increasing concentrations of 
the compounds and then treated with INF (10 ng/mL) for another 12 h. 
After stimulation, cells were washed twice with PBS and lysed in 25 mM Tris-
phosphate pH 7.8, 8 mM MgCl2, 1 mM DTT, 1% Triton X-100 and 7% glycerol 
for 15 min at room temperature in a horizontal shaker. Following 
centrifugation, the supernatant was used to measure luciferase activity using 
an Autolumat LB 9510 (Berthold) following the instructions of the luciferase 
assay kit (Promega, Madison, WI, USA). 
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4.4.6 Cell cycle analysis 
 The percentage of cells in each phase of the cell cycle was determined by 
flow cytometry. Briefly DU145 cells were collected after treatments, washed 
twice with PBS, and fixed with ethanol (70%, for 24 h at 4 °C). Then the cells 
were washed trice with PBS containing 4% glucose, subjected to RNA 
digestion (RNase A, 50 units/ml) and propidium iodide (20 g/mL) staining 
in PBS for 1 h at room temperature, and analyzed by flow cytometry in a 
FACSCanto II flow cytometer. Ten thousand gated events were collected per 
sample, and the percentage of cells in each phase of the cell cycle was 
analyzed by using BD FACSDiva™software. 
4.4.7 Assessment of transmission blocking activity in vivo 
The in vivo transmission blocking effect of V. amygdalina was estimated by 
determining oocyst prevalence and density in mosquitoes fed on extract-
treated gametocytaemic mice.35 Briefly, mice were inoculated with 107 P. 
berghei GFPcon-infected red blood cells (RBCs) through the intraperitoneal 
(i.p.) route. On day three post-infection, animals allocated to the treatment 
groups were  treated i.p. with 500 mg/kg and 100 mg/kg (maximum 
tolerable dose) of Ver-H2O and Ver-EtOH., respectively, while control animals 
received 200 µL of the solvents used to dissolve the extracts. On day four 
post-infection, the treatment was repeated 1 h before the exposure of the 
mice to mosquitoes (day 4 gametocytes yield consistently high mosquito 
infections in this model). Mice were anaesthetized and kept on top of 
mosquito cages containing 150 to 200 An. stephensi females for 1 h. Unfed 
females were removed the following day. On day 10/11 after the blood meal, 
17  34 mosquitoes from each cage were dissected. Oocyst prevalence and 
density were assessed by counting the number of green fluorescent oocysts 
on mosquito mid-guts under a fluorescence microscope (ZEISS Axio Observer 
Z1, FITC filter 9). Oocyst density was determined by calculating the geometric 
mean of the number of oocysts recorded on oocyst positive mosquitoes.61 
Geometric mean =     , 
where n= Number of oocyst positive mosquitoes, x= Oocyst number per 
mosquito. 
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The percent reduction of oocyst density in treatment groups was calculated 
as follows:                                                
       
Percent reduction of oocyst density =  1 -                                                     x100 
                                                                               
The experiment was conducted in triplicate, using for each treatment group 
three mice and for each mouse one cage of mosquitoes. 
average oocyst density in a control 
group 
 average oocyst density in treated group 
 
 average oocyst density in treated group 
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CHAPTER 5 -CONCLUSIONS 
With over 60% of drugs on the market of natural origin or inspired by 
natural compounds, the investigation of natural products can be considered 
as the foundation of the pharmaceutical industry. This PhD thesis was 
focused on the investigation of bioactive secondary metabolites from 
different natural sources (terrestrial plants and marine sponges) and the 
research activity described led to the discovery of new chemistry with 
potential pharmaceutical and biochemical applications.  
Results obteined from my research work show that natural sources (plants 
and marine organisms) represent, once again, a very imporant way to obtain 
molecules with important pharmacological activities. 
A demonstration of the impact of natural products chemistry in the discovery 
of important scaffolds for the design of new drugs, is the high 
antiproliferative activity showed by swinholides from the sponge Theonella 
swinhoei. Similarly, complex peptide structure in theonellapeptolides is 
worth considering and deserves additional chemical and pharmacological 
investigation. To examine these apects, a project aimed to the synthesis of 
these molecules is underway. 
In the case of research on Vernonia amygdalina, the transition from 
traditional use of a plant as food and as remedy, to the step of phytochemical 
analysis, then to the isolation of pharmacologically active metabolites, to the 
step of drug manufacturing on industrial scale, is going to be completed. 
Based on the results obtained during my PhD, a project of production of a 
multi-stage antimalarial phytomedicine based on standardized extracts 
enriched in vernodalol is currently in development by University of Camerino 
industrial spin-off, named Pro Herbal Care. 
In conclusion, natural product chemistry are an old research field but they 
can still be considered as an expanding field of research, that holds a lot in 
store for the future. 
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CHAPTER 6 -SPECTRAL DATA 
 
Spectral data for CHAPTER 2 
 
1H spectrum (700 MHz) of isoswinholide B (5) in CD3OD 
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COSY spectrum (700 MHz) of isoswinholide B (5) in CD3OD 
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HMBC spectrum (700 MHz) of isoswinholide B (5) in CD3OD 
 
 
HSQC spectrum (700 MHz) of isoswinholide B (5) 
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1H spectrum (700 MHz) of swinholide K (6) in CD3OD 
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COSY spectrum (700 MHz) of swinholide K (6) in CD3OD 
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HMBC spectrum (700 MHz) of swinholide K (6) in CD3OD 
 
HSQC spectrum (700 MHz) of swinholide K (6) in CD3OD 
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1H spectrum (500 MHz) of sulfinyltheonellapeptolide (8) in CD3OD 
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COSY  spectrum (500 MHz) of sulfinyltheonellapeptolide (8) in CD3OD 
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HMBC  spectrum (500 MHz) of sulfinyltheonellapeptolide (8) in CD3OD 
 
 
HSQC  spectrum (500 MHz) of sulfinyltheonellapeptolide (8) in CD3OD 
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1H  spectrum (500 MHz) of theonellapeptolide If  (9) in CD3OD 
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COSY  spectrum (500 MHz) of theonellapeptolide If  (9) in CD3OD 
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HMBC  spectrum (500 MHz) of theonellapeptolide If  (9) in CD3OD 
 
 
 
 
Chapter  6-Spectral data 
131 
 
Spectral data for CHAPTER 3 
1H  spectrum (600 MHz) of compound (9) in DMSO 
 
 
 
 
 
 
 
 
 
COSY  spectrum (600 MHz) of compound (9) in DMSO 
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HMBC  spectrum (600 MHz) of compound (9) in DMSO 
 
 
DEPT-Q  spectrum (600 MHz) of compound (9) in DMSO 
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Spectral data for CHAPTER 4 
1H  spectrum (500 MHz) of methylvernoilide (13) in CDCl3 
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COSY  spectrum (500 MHz) of methylvernoilide (13) in CDCl3 
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1H  spectrum (500 MHz) of deoxyvernodalol (14) in CDCl3 
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1H  spectrum (500 MHz) of vernomygdalin (15) in CDCl3 
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COSY  spectrum (500 MHz) of vernomygdalin (15) in CDCl3 
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HMBC  spectrum (500 MHz) of vernomygdalin (15) in CDCl3 
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1H  spectrum (500 MHz) of vernolide (8) in DMSO 
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1H  spectrum (500 MHz) of vernodalol (9) in DMSO 
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Low-field region of the 1H NMR spectrum (500 MHz) of a 1:1 mixture of 
vernolide (8) and vernodalol (9) in DMSO-d6. 
 
 
 
 
Low-field region of the 1H NMR spectrum (500 MHz) of a 1:1 mixture of 
vernolide (8) and vernodalol (9) in DMSO-d6 15 min. after addition of 1 
equiv. of cysteamine 
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